Formulations and methods for treating ophthalmic conditions
Patent Information
- Application Number
- JP2023530994
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-12
- Filing Date
- 2021-11-23
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for dry eye disease (DED) and blepharitis, particularly those related to meibomian gland dysfunction, are primarily symptomatic and lack a long-term cure, with existing formulations being ineffective or unsafe for chronic use, and there are no FDA-approved treatments for blepharitis.
Pharmaceutical formulations containing sub-antimicrobial doses of azithromycin, sub-antiparasitic doses of avermectin, and dicarboxylic acids like azelaic acid are applied directly to the eyelids to alter meibum lipid chemistry, improving secretion and quality, thereby alleviating symptoms of DED and blepharitis.
The formulations safely treat chronic DED and blepharitis by restoring meibum lipid chemistry, enhancing secretion, and maintaining tear film stability over extended periods, reducing symptoms such as redness, stinging, and blurred vision.
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 117,393, filed November 23, 2020, and U.S. Provisional Application No. 63 / 254,958, filed October 12, 2021, the disclosures of each of which are incorporated by reference herein in their entirety.
[0002] Technical Field The present disclosure relates generally to treating ophthalmic diseases or conditions. [Background technology]
[0003] background Dry eye disease (DED) encompasses several disease states, defined by the TFOS DEWS II (Ocul. Surf., 2017, 15(3), 269-650) as "a multifactorial disorder of the ocular surface characterized by loss of tear film homeostasis, with ocular symptoms in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play a pathogenetic role." DED can generally be divided into two classes: aqueous-deficient dry eye (ADDE) and evaporative dry eye (EDE), each of which can be further divided into subclasses. One of the major symptoms associated with DED, particularly EDE, is meibomian gland dysfunction (MGD), an umbrella term encompassing several disorders. The destruction and blockage of meibomian glands adversely affect the quality and quantity of meibum, a lipid-rich secretion that protects the ocular surface from tear damage and premature evaporation (Chhadva, et al., Ophthalmology, 2017, 124(11 Suppl), S20-S26). Approximately 20-40 meibomian glands are present in each eyelid, producing meibum, which coats the tear film and prevents premature tear evaporation. When meibomian glands are healthy, patent, and functioning properly, meibum has a liquid, olive-oil-like consistency. Each blink exerts a compressive force on the meibomian glands, squeezing some of the clear liquid meibum out of the gland opening, strengthening the outermost lipid layer of the tear film. In MGD-based EDE, the development of an imbalance in natural lipids and lipid chemistry leads to a higher meibum melting temperature, ultimately causing the meibum to transition from a healthy, clear, liquid state through a cloudy, semi-rigid state to an advanced, pathologically rigid state. Ultimately, as the disease progresses and meibum lipid chemistry deteriorates, the rigid meibum becomes inaccessible and uncompressible, resulting in a poor-quality tear lipid layer and premature tear evaporation. In obstructive MGD, blinking results in little or no meibum expression due to the rigid physicochemical state and incompressibility of the meibum, the damaged lipid layer, and accelerated tear evaporation.
[0004] Globally, the prevalence of dry eye disease (DED) is estimated to be 5-20%, with approximately 16 million Americans diagnosed. It is estimated that 86% of these DED patients have MGD-related EDE (Lemp, et al., Cornea, 2012, pp. 472-478). Individuals with DED suffer from insufficient tear production, poor tear quality, or both, resulting in redness, stinging, burning, itching, light sensitivity, watery eyes, blurred vision, ocular surface irregularities, and damage to the corneal or conjunctival epithelium and tissues. The majority of dry eye patients are believed to have at least some degree of both aqueous tear deficiency and lipid deficiency. Treatment is primarily symptomatic, and no widespread cure for DED has been developed.
[0005] Relatedly, blepharitis, which may be associated with MGD, is an inflammatory condition of the eyelids that can cause irritation, redness, itching, burning, swelling, and crusting, among other symptoms. Blepharitis can result in permanent changes to the eyelid margins. Symptoms are generally divided into two categories based on location. Anterior blepharitis occurs on the outer edge of the eyelid and is typically associated with bacterial infection. Posterior blepharitis, which occurs on the inner edge of the eyelid, can occur when the meibomian glands produce reduced or poor-quality meibum, leading to excessive evaporation of water from the ocular surface.
[0006] Currently, there are no FDA-approved treatments for blepharitis, and only four FDA-approved medications for treating dry eye (Restasis®, Xiidra®, Cequa®, and Eysuvis®), all of which act to reduce the inflammatory aspects of the condition. If a bacterial infection occurs, topical or oral antibiotics may be administered, but these may not treat the underlying cause of the disease, and long-term use may result in undesirable toxicity or side effects. Therefore, available treatment strategies are primarily symptomatic and centered on maintaining proper eyelid hygiene. Eyelid warming using hot compresses is a standard eyelid treatment for increasing meibum fluidity in patients with obstructed meibomian glands, but hot compresses are imprecise and often ineffective (i.e., too hot, do not stay hot long enough, cool too quickly to cool effectively, or do not conform well to the eyelid to achieve the required elevated meibum melting temperature), compliance is problematic, and prolonged use can result in thermal injury to ocular tissues. Opening of obstructed meibomian glands by physical squeezing or eyelid massage can improve secretion and dry eye symptoms, but as with hot compresses, compliance remains an issue, the required procedures can cause damage to sensitive tissues (e.g., unwanted corneal remodeling due to rubbing of the eyelid and applying unwanted pressure to the cornea), and the therapeutic effect is short-lived. Thus, there is a need for effective long-term methods of treating ocular disorders, including DED and blepharitis, particularly when the disorders are due to blocked meibomian glands with hardened meibum, and when the disorders persist chronically for months, years, or a lifetime. [Prior art documents] [Non-patent literature]
[0007] [Non-Patent Document 1] TFOS DEWS II(Ocul.Surf.,2017,15(3),269-650) [Non-patent document 2] Chhadva,et al.,Ophthalmology,2017,124(11 Suppl),S20-S26 [Non-patent document 3] Lemp,et al.,Cornea,2012,472-478 Summary of the Invention [Means for solving the problem]
[0008] Abstract Disclosed herein are formulations and methods for treating dry eye disease.In some embodiments, a method for treating dry eye disease in a subject in need thereof can comprise administering to the subject a pharmaceutical formulation comprising a sub-antibiotic dose of azithromycin.The method can comprise administering the pharmaceutical formulation to the eyelid.The method can also comprise administering the pharmaceutical formulation daily for at least one month.
[0009] In some embodiments, a method for treating blepharitis in a subject in need thereof is disclosed, and can include administering to the subject a pharmaceutical preparation comprising a sub-antibacterial dose of azithromycin.The method can include administering the pharmaceutical preparation to the eyelid.The method can also include administering the pharmaceutical preparation daily for at least one month.
[0010] In another aspect, a method for increasing meibum secretion in a subject in need thereof is disclosed, and may include administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin. The method may include administering the pharmaceutical formulation to the eyelid. The method may also include administering the pharmaceutical formulation daily for at least one month.
[0011] In some embodiments, a method for treating dry eye disease in a subject in need thereof comprises administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin. The method may comprise administering the pharmaceutical formulation to the eyelid. The method may also comprise administering the pharmaceutical formulation daily for at least one month.
[0012] In some embodiments, a method for treating blepharitis in a subject in need thereof can include administering to the subject a pharmaceutical preparation comprising a sub-antiparasitic dose of avermectin.The method can include administering the pharmaceutical preparation to the eyelid.The method can also include administering the pharmaceutical preparation daily for at least one month.
[0013] In another aspect, a method for increasing meibum secretion in a subject in need thereof can include administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin. The method can include administering the pharmaceutical formulation to the eyelid. The method can also include administering the pharmaceutical formulation daily for at least one month.
[0014] In another embodiment, the method for treating dry eye disease or blepharitis in a subject who needs to be treated can include administering a pharmaceutical formulation of azelaic acid to the subject.The method can include administering the pharmaceutical formulation to the eyelid.The administration of such a pharmaceutical formulation can alleviate the symptoms of dry eye disease or blepharitis.The method can also include administering the pharmaceutical formulation daily for at least one month.
[0015] In another aspect, a method for increasing meibum secretion in a subject can include administering a pharmaceutical formulation of azelaic acid. The method can include administering the pharmaceutical formulation to the eyelid. Administration of such a pharmaceutical formulation can alleviate symptoms of insufficient tear production or poor tear quality.
[0016] In another embodiment, a method for treating dry eye disease, blepharitis, or increasing meibum secretion in a subject in need thereof may include administering a pharmaceutical formulation to the eyelid of the subject. The pharmaceutical formulation may comprise about 1% to about 20% azelaic acid. The pharmaceutical formulation may comprise about 0.1% to about 0.5% azithromycin. The method may further include administering the pharmaceutical formulation daily for at least one month.
[0017] Pharmaceutical formulations are also disclosed herein. In some embodiments, pharmaceutical formulations for treating ophthalmic conditions may include a sub-antibacterial dose of azithromycin. Pharmaceutical formulations for treating ophthalmic conditions may include a sub-antiparasitic dose of avermectin.
[0018] In other aspects, pharmaceutical formulations for treating ophthalmic conditions may comprise a sub-antibacterial dose of azithromycin and a sub-antiparasitic dose of avermectin. Pharmaceutical formulations for treating ophthalmic conditions may comprise a sub-antibacterial dose of azithromycin and a sub-antiparasitic dose of avermectin, and may further comprise an immunosuppressant.
[0019] In other embodiments, pharmaceutical formulations for treating ocular conditions may include a sub-antibacterial dose of azithromycin or a sub-antiparasitic dose of avermectin and azelaic acid. DETAILED DESCRIPTION OF THE INVENTION
[0020] Detailed Description The following description, for purposes of explanation, uses specific nomenclature to provide a thorough understanding of the invention. However, it will be apparent to those skilled in the art that specific details are not required to practice the present invention. Thus, the foregoing descriptions of specific embodiments of the present invention are presented for purposes of illustration and description. The foregoing description is not intended to be exhaustive or to limit the invention to the precise form disclosed; obviously, many modifications and embodiments are possible in light of the teachings disclosed herein.
[0021] Described herein are embodiments of pharmaceutical formulations and methods for treating ophthalmic conditions. For example, pharmaceutical formulations and methods such as those described herein can be used to treat dry eye disease (DED). In some embodiments, such formulations and methods can be used to treat blepharitis. In some embodiments, the blepharitis is caused by Demodex mites, while in other embodiments, the blepharitis is not caused by Demodex mites. As another example, in some embodiments, such formulations and methods can be used to increase or enhance meibum secretion. In some embodiments, such formulations and methods can be used to increase meibum secretion or improve meibum quality.
[0022] As used herein, "treating" or "treating" a disease or condition can mean alleviating, alleviating, and / or eliminating one or more symptoms of the disease or condition. For example, the methods of treating dry eye disease disclosed herein can result in the alleviation of one or more symptoms of dry eye disease.
[0023] Currently, there are few effective long-term formulations or treatment methods for ocular conditions such as dry eye disease and blepharitis. Commercially approved treatments are limited and target specific symptoms or causes, such as inflammation or bacterial infection. In contrast, the formulations and methods described herein offer several advantages, including the ability to administer long-term and generally improve meibum quality and increase secretion in individuals who benefit thereby. Further beneficial features are described in more detail below. Pharmaceutical preparations
[0024] Generally, in some embodiments, pharmaceutical formulations for treating ocular conditions may contain an antibiotic, an antiparasitic, and / or a dicarboxylic acid (e.g., azelaic acid). For example, the antibiotic may be azithromycin. In particular, these formulations may contain a sub-antibacterial dose of an antibiotic, such as azithromycin. "Sub-antibacterial," as used herein, refers to an amount or concentration of an antibiotic that is below the amount or concentration typically administered to kill bacteria or inhibit bacterial growth, or below the amount or concentration clinically useful for killing bacteria or inhibiting bacterial growth. For example, a sub-antibacterial amount of azithromycin may be less than 1%. For clarity, the percentages of components of the formulations described herein may refer to w / v, w / w, or v / v percentages. For example, "less than 1%" may be read to mean less than 1% weight / volume (% w / v), less than 1% weight / weight (% w / w), or less than 1% volume / volume (% v / v). In some embodiments, pharmaceutical formulations for treating ophthalmic conditions may include brimonidine, oxymetazoline, or metronidazole.
[0025] In particular, the subantimicrobial formulations disclosed herein are contrasted with commercially available antibiotic formulations used in ophthalmic applications. For example, AzaSite® and Klarity-A™ contain 1% azithromycin and are used to treat bacterial conjunctivitis or eye infections. Azyter® is another commercially available ophthalmic formulation containing 1.5% azithromycin. However, formulations such as Azasite®, Klarity-A™, and Azyter® are not suitable for long-term use. AzaSite's label states, "Long-term use may result in the overgrowth of non-susceptible organisms, including fungi," potentially leading to new and more difficult-to-treat infections. Furthermore, U.S. Patent No. 8,349,806 discloses AzaSite's anti-inflammatory mechanism of action, but in 2011, the FDA stated that claims that AzaSite has anti-inflammatory properties have not been clinically verified. Klarity-A™ lists possible adverse effects such as eye irritation, blurred vision, contact dermatitis, corneal erosion, decreased vision, abnormal taste, eye pain, facial edema, eye reactions (burning, eye discharge, stinging), nasal congestion, sinusitis, eye swelling, and skin rash.
[0026] In contrast to commercially available antibiotic preparations, the subantimicrobial pharmaceutical formulations of the present disclosure are useful and safe for the long-term (e.g., at least one month, several years) treatment of chronic ocular disorders that are not due to infection or inflammation of intraocular or periocular tissues. Instead, relatively low doses of the subantimicrobial formulations described herein alter the lipid chemistry of meibum, lowering its phase transition temperature and melting point, thereby helping to liquefy, loosen, or soften hardened meibum at any temperature, including normal ambient, physiological, body, and eyelid temperatures, ensuring consistent, natural expression of meibum from the meibomian glands onto the tear fluid via the blinking mechanism. In doing so, a healthy, protective outer lipid layer of tear fluid is restored and strengthened, preventing accelerated, premature tear evaporation. This can alleviate the symptoms of chronic DED and blepharitis associated with blocked meibomian glands, hardened, unavailable meibum, or poor-quality meibum. Furthermore, in some embodiments, pharmaceutical formulations can maintain the quality of meibum secreted by healthy individuals over the long term, thus preventing MGD or MGD-related EDE. Previous studies have shown that antibacterial levels of azithromycin (1%) can improve meibum lipid phase transition temperature and lipid ordering (Foulks, et al., Cornea, 2010, 29(7)). The pharmaceutical formulations disclosed herein can improve meibum lipid phase transition temperature and lipid ordering at lower concentrations over an extended period of time. The methods and formulations described herein can alleviate symptoms of insufficient tear production or poor tear quality. In some embodiments, symptoms of insufficient tear production or poor tear quality can be redness, stinging, burning, itching, light sensitivity, watery eyes, blurred vision, ocular surface irregularities, or damage to the corneal or conjunctival epithelium and tissues. In some embodiments, antiparasitic pharmaceutical formulations can address posterior blepharitis.
[0027] Pharmaceutical formulations for treating ocular conditions may contain dicarboxylic acids such as azelaic acid. Azelaic acid (nonanedioic acid) is a saturated dicarboxylic acid with anti-inflammatory properties that is used in commercially available formulations for the treatment of acne and rosacea. Approved commercial products such as FINACEA and AZELEX contain high concentrations of azelaic acid (15% and 20%, respectively). Pharmaceutical formulations of the present disclosure containing dicarboxylic acids (e.g., azelaic acid) are useful and safe for the long-term treatment (e.g., at least 1 month, at least 6 months, at least 1 year) of chronic ocular disorders that are not caused by infection or inflammation of intraocular or periocular tissues. Specifically, the pharmaceutical formulations disclosed herein may act on the anterior eyelid to treat ocular conditions such as MGD, MGD-related EDE, or blepharitis in, at, or around the orifices of the meibomian glands. Dicarboxylic acids (e.g., azelaic acid) may also have anti-inflammatory, antioxidant, antibacterial, or anti-keratinizing properties that complement the treatment of anterior eyelid conditions. When used as described herein, dicarboxylic acids can promote cell turnover, promote the removal of dead cells, reduce keratin at the eyelid margin, and / or assist in exfoliating the eyelid margin, improving the keratinization seen in MGD. Dicarboxylic acids can also kill Demodex mites and / or promote an environment that is sufficiently hostile for Demodex mites, thereby reducing the viability of Demodex mites. In some embodiments, dicarboxylic acids (e.g., azelaic acid) can address anterior blepharitis.
[0028] In the case of a dicarboxylic acid (e.g., azelaic acid), the pharmaceutical formulations described herein can contain about 1% to about 20% of the dicarboxylic acid (e.g., azelaic acid). In some embodiments, the pharmaceutical formulations contain about 1% to 5%, 5% to 10%, 10% to 15%, or 15% to 20% of the dicarboxylic acid (e.g., azelaic acid). In some embodiments, the pharmaceutical formulations comprise a solubility limiting agent selected from the group consisting of about 1% to 2%; 2% to 20%; 2% to 18%; 2% to 16%; 2% to 14%; 2% to 12%; 2% to 10%; 2% to 8%; 2% to 6%; 2% to 4%; 4% to 20%; 4% to 18%; 4% to 16%; 4% to 14%; 4% to 12%; 4% to 10%; 4% to 8%; 4% to 6%; 6% to 20%; 6% to 18%; 6% to 16%; 6% to 14%; 6% to 12%; 6% to 10%; 6% to 8%; Contains 8% to 20%; 8% to 18%; 8% to 16%; 8% to 14%; 8% to 12%; 8% to 10%; 10% to 20%; 10% to 18%; 10% to 16%; 10% to 14%; 10% to 12%; 12% to 20%; 12% to 18%; 12% to 16%; 12% to 14%; 14% to 20%; 14% to 18%; 14% to 16%; 16% to 20%; 16% to 18%; or 18% to 20% dicarboxylic acid (e.g., azelaic acid). In some embodiments, the pharmaceutical formulation comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% dicarboxylic acid (e.g., azelaic acid).
[0029] In some embodiments, pharmaceutical preparations for treating eye conditions can include antiparasitic drugs.For example, the antiparasitic drug can be avermectin.In particular, these preparations can include antiparasitic drugs, such as avermectin, at sub-antiparasitic doses.As used herein, "sub-antiparasitic" refers to an amount or concentration of an antiparasitic agent that is less than the amount or concentration that is typically administered to kill parasites or inhibit the growth or reproduction of parasites, or an amount or concentration of an antibiotic that is less than the amount or concentration that is clinically useful to kill parasites or inhibit the growth or reproduction of parasites.
[0030] The sub-antiparasitic formulations disclosed herein are compared to commercially available formulations of antibiotics used in ophthalmic applications. For example, the sub-antiparasitic amount of avermectin can be less than 1%. In some embodiments, the sub-antiparasitic avermectin of the disclosed formulations can be ivermectin, selamectin, doramectin, eprinomectin, or abamectin. In some embodiments, the avermectin is ivermectin.
[0031] In particular, the subantiparasitic formulations disclosed herein are contrasted with commercially available formulations of antiparasitic drugs. For example, the commercially available formulation Soolantra® is a topical 1% ivermectin cream used to treat rosacea. FDA labeling specifies that Soolantra® should not be used for ophthalmic purposes. In one clinical trial (see https: / / www.accessdata.fda.gov / drugsatfda_docs / nda / 2014 / 206255Orig1s000MedR.pdf), a 52-week open-label study using 1% ivermectin was terminated early at week 10 due to abnormal laboratory findings, i.e., low neutrophil counts. Notably, lower concentrations (e.g., 0.1% and 0.35%) lose efficacy for their intended rosacea treatment. Additional safety concerns regarding 1% ivermectin cream include nasopharyngitis, headache, and upper respiratory tract infections.
[0032] In contrast to topical antiparasitic formulations, the antiparasitic sub-pharmaceutical formulations of the present disclosure are useful and safe for the long-term (e.g., at least one month, several years) treatment of chronic ocular disorders that are not due to parasitic infection or inflammation of intraocular or periocular tissues. As described above for sub-antibacterial formulations, the relatively low doses of the antiparasitic sub-pharmaceutical formulations described herein instead alter the lipid chemistry of meibum, loosening or softening hardened meibum to ensure consistent, natural expression from the meibomian glands. In doing so, they can alleviate the symptoms of chronic DED and blepharitis associated with blocked glands, hardened, unavailable meibum, or low-quality meibum. Furthermore, in some embodiments, the pharmaceutical formulations can maintain the quality of meibum secreted by healthy individuals over the long term, thus preventing MGD or MGD-related EDE. In some embodiments, the antiparasitic sub-pharmaceutical formulations can address posterior blepharitis.
[0033] As noted above, a sub-antibacterial formulation may have less than 1% antibiotic, and a sub-antiparasitic formulation may have less than 1% antiparasitic. In some embodiments, the pharmaceutical formulation contains less than 1% azithromycin. In some embodiments, the pharmaceutical formulation contains 0.5% or less azithromycin. In some embodiments, the pharmaceutical formulation contains 0.1% or less azithromycin. In some embodiments, the pharmaceutical formulation contains 0.01% or less azithromycin. In some embodiments, the pharmaceutical formulation contains 0.001% or less azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.5% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.1% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.01% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.001% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.5% to about 1% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.1% to about 1% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.01% to about 1% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.001% to about 1% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.01% to about 0.1% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.001% to about 0.1% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.001% to about 0.1% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.001% to about 0.01% azithromycin. In some embodiments, the pharmaceutical formulation contains about 0.4% to about 0.5% azithromycin. In some embodiments, the pharmaceutical formulation may further comprise a dicarboxylic acid (e.g., azelaic acid). The pharmaceutical formulation may, for example, comprise any concentration of azithromycin and any concentration of a dicarboxylic acid (e.g., azelaic acid) described herein. In some embodiments, the pharmaceutical formulation comprises about 1% to about 20% of a dicarboxylic acid (e.g., azelaic acid). In some embodiments, the pharmaceutical formulation comprises about 1% to 5%, 5% to 10%, 10% to 15%, or 15% to 20% of a dicarboxylic acid (e.g., azelaic acid).In some embodiments, the pharmaceutical formulations comprise a solubility limiting agent selected from the group consisting of about 1% to 2%; 2% to 20%; 2% to 18%; 2% to 16%; 2% to 14%; 2% to 12%; 2% to 10%; 2% to 8%; 2% to 6%; 2% to 4%; 4% to 20%; 4% to 18%; 4% to 16%; 4% to 14%; 4% to 12%; 4% to 10%; 4% to 8%; 4% to 6%; 6% to 20%; 6% to 18%; 6% to 16%; 6% to 14%; 6% to 12%; 6% to 10%; 6% to 8%; Contains 8% to 20%; 8% to 18%; 8% to 16%; 8% to 14%; 8% to 12%; 8% to 10%; 10% to 20%; 10% to 18%; 10% to 16%; 10% to 14%; 10% to 12%; 12% to 20%; 12% to 18%; 12% to 16%; 12% to 14%; 14% to 20%; 14% to 18%; 14% to 16%; 16% to 20%; 16% to 18%; or 18% to 20% dicarboxylic acid (e.g., azelaic acid). In some embodiments, the pharmaceutical formulation comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% dicarboxylic acid (e.g., azelaic acid).
[0034] Table 1 shows exemplary formulations of sub-antibacterial doses of azithromycin in combination with azelaic acid. [Table 1]
[0035] In the case of sub-antiparasitic formulations, the pharmaceutical formulation may have less than 1% avermectin. In some embodiments, the pharmaceutical formulation contains 0.5% or less avermectin. In some embodiments, the pharmaceutical formulation contains 0.1% or less avermectin. In some embodiments, the pharmaceutical formulation contains 0.01% or less avermectin. In some embodiments, the pharmaceutical formulation contains 0.001% or less avermectin. In some embodiments, the pharmaceutical formulation contains about 0.5% avermectin. In some embodiments, the pharmaceutical formulation contains about 0.1% avermectin. In some embodiments, the pharmaceutical formulation contains about 0.01% avermectin. In some embodiments, the pharmaceutical formulation contains about 0.001% avermectin. In some embodiments, the pharmaceutical formulation contains about 0.5% to about 1% avermectin. In some embodiments, the pharmaceutical formulation contains about 0.1% to about 1% avermectin. In some embodiments, the pharmaceutical formulation contains about 0.01% to about 1% avermectin. In some embodiments, the pharmaceutical formulation contains about 0.001% to about 1% avermectin. In some embodiments, the pharmaceutical formulation contains about 0.01% to about 0.1% avermectin. In some embodiments, the pharmaceutical formulation contains about 0.001% to about 0.1% avermectin. In some embodiments, the pharmaceutical formulation contains about 0.001% to about 0.01% avermectin. In some embodiments, the pharmaceutical formulation may further contain a dicarboxylic acid (e.g., azelaic acid). The pharmaceutical formulation may contain, for example, any concentration of avermectin and any concentration of a dicarboxylic acid (e.g., azelaic acid) described herein. In some embodiments, the pharmaceutical formulation comprises about 1% to about 20% of a dicarboxylic acid (e.g., azelaic acid), 1% to 5%, 5% to 10%, 10% to 15%, or 15% to 20% of a dicarboxylic acid (e.g., azelaic acid).In some embodiments, the pharmaceutical formulations comprise a solubility limiting agent selected from the group consisting of about 1% to 2%; 2% to 20%; 2% to 18%; 2% to 16%; 2% to 14%; 2% to 12%; 2% to 10%; 2% to 8%; 2% to 6%; 2% to 4%; 4% to 20%; 4% to 18%; 4% to 16%; 4% to 14%; 4% to 12%; 4% to 10%; 4% to 8%; 4% to 6%; 6% to 20%; 6% to 18%; 6% to 16%; 6% to 14%; 6% to 12%; 6% to 10%; 6% to 8%; Contains 8% to 20%; 8% to 18%; 8% to 16%; 8% to 14%; 8% to 12%; 8% to 10%; 10% to 20%; 10% to 18%; 10% to 16%; 10% to 14%; 10% to 12%; 12% to 20%; 12% to 18%; 12% to 16%; 12% to 14%; 14% to 20%; 14% to 18%; 14% to 16%; 16% to 20%; 16% to 18%; or 18% to 20% dicarboxylic acid (e.g., azelaic acid). In some embodiments, the pharmaceutical formulation comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% dicarboxylic acid (e.g., azelaic acid).
[0036] As described above, a sub-antibacterial antibiotic or sub-antiparasitic antiparasitic formulation alone may be sufficient and safe for treating chronic ocular conditions. However, in some cases, it may be beneficial to administer a combined formulation of both an antiparasitic and an antibiotic to achieve a more robust effect. This increased effect may be the result of a synergistic effect between the two agents in their ability to increase the quantity and / or quality of meibum produced. Similarly, such a synergistic effect may be obtained by combining azithromycin with a dicarboxylic acid (e.g., azelaic acid) or ivermectin with a dicarboxylic acid (e.g., azelaic acid).
[0037] For example, in some embodiments, a pharmaceutical formulation may have both azithromycin and avermectin. In some embodiments, a pharmaceutical formulation comprises azithromycin at a sub-antibacterial dose and further comprises avermectin. In some embodiments, a pharmaceutical formulation comprises azithromycin at a sub-antibacterial dose and further comprises 1% or more avermectin. In some embodiments, a pharmaceutical formulation comprises avermectin at a sub-antibacterial dose and further comprises 1% or more azithromycin. In some embodiments, a pharmaceutical formulation comprises azithromycin at a sub-antibacterial dose and further comprises avermectin at a sub-antiparasitic dose. In some embodiments, a pharmaceutical formulation comprises azithromycin at a sub-antibacterial dose and further comprises avermectin at a sub-antiparasitic dose. In some embodiments, a pharmaceutical formulation comprises azithromycin at a sub-antibacterial dose, avermectin at a sub-antiparasitic dose, and a dose of a dicarboxylic acid (e.g., azelaic acid).
[0038] The formulations of the present disclosure can be delivered to the outer surface of the eyelid via a topical route. For example, the pharmaceutical formulations can be applied (e.g., administered) as solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, sprays, drops, and aerosols via applicator sticks, contact lenses, ophthalmic inserts, cul-de-sac inserts, and fornix inserts. The formulations of the present disclosure can further contain components for sustained release and / or comfort. Such components include high-molecular-weight, anionic mucosomimetic polymers, gelling polysaccharides, and finely divided drug carrier substrates. The formulations can also be mounted on a patch with an absorbable adhesive or a fully or partially bioabsorbable patch that is applied to one or more eyelids.
[0039] One advantage of the pharmaceutical formulations disclosed herein is that they can be applied directly to the eyelids rather than systemically. Application to the eyelids allows the formulation to reach the meibomian glands most directly, where the quantity and / or quality of meibum may be improved. The pharmaceutical formulation may contain at least one skin penetration enhancer to aid in the penetration of subantibacterial doses of azithromycin, subantiparasitic doses of avermectins, and / or dicarboxylic acids (e.g., azelaic acid) through the eyelids to reach the meibomian glands. In some embodiments, the skin penetration enhancer is selected from polyethylene glycol, propylene glycol, sodium lauryl sulfate, and ceramide. In some embodiments, the pharmaceutical formulation contains from about 0.1% to about 5% of the skin penetration enhancer. In some embodiments, the pharmaceutical formulation contains from about 0.1% to about 1% of the skin penetration enhancer. In some embodiments, the pharmaceutical formulation contains from about 0.1% to about 0.25% of the skin penetration enhancer. In some embodiments, the pharmaceutical formulation comprises about 1% to about 5% of a skin penetration enhancer. In some embodiments, the pharmaceutical formulation comprises about 1% to about 4% of a skin penetration enhancer. In some embodiments, the pharmaceutical formulation comprises about 1% to about 3% of a skin penetration enhancer. In some embodiments, the pharmaceutical formulation comprises about 1% to about 2% of a skin penetration enhancer. In some embodiments, the pharmaceutical formulation comprises about 2% to about 5% of a skin penetration enhancer. In some embodiments, the pharmaceutical formulation comprises about 2% to about 4% of a skin penetration enhancer. In some embodiments, the pharmaceutical formulation comprises about 2% to about 3% of a skin penetration enhancer. In some embodiments, the pharmaceutical formulation comprises about 3% to about 5% of a skin penetration enhancer. In some embodiments, the pharmaceutical formulation comprises about 3% to about 4% of a skin penetration enhancer.
[0040] Exemplary formulations of sub-antibacterial doses of azithromycin in combination with skin penetration enhancers are shown in Table 2. [Table 2]
[0041] Exemplary formulations of azelaic acid in combination with a skin penetration enhancer are shown in Table 3. [Table 3]
[0042] Exemplary formulations of sub-antibacterial doses of avermectins in combination with skin penetration enhancers are shown in Table 4. [Table 4]
[0043] In some embodiments, the formulations described herein may contain at least one polyol. Thus, adding a polyol to the formulations described herein may increase the solubility of one or more of the components described herein (e.g., azithromycin, azelaic acid). In some embodiments, the polyol is propylene glycol, polyethylene glycol, glycerol, erythritol, mannitol, or sorbitol. In some embodiments, the pharmaceutical formulation contains about 0.1% to about 20% polyol. In some embodiments, the pharmaceutical formulation contains about 0.1% to about 15% polyol. In some embodiments, the pharmaceutical formulation contains about 0.1% to about 10% polyol. In some embodiments, the pharmaceutical formulation contains about 0.1% to about 5% polyol. In some embodiments, the pharmaceutical formulation contains about 1% to about 20% polyol. In some embodiments, the pharmaceutical formulation contains about 1% to about 15% polyol. In some embodiments, the pharmaceutical formulation comprises about 1% to about 10% polyol. In some embodiments, the pharmaceutical formulation comprises about 1% to about 5% polyol. In some embodiments, the pharmaceutical formulation comprises about 1% to about 4%, about 4% to about 20%, about 4% to about 16%, about 4% to about 12%, about 4% to about 8%, 8% to about 20%, about 8% to about 16%, about 8% to about 12%, about 12% to about 20%, about 12% to about 16%, or about 16% to about 20% polyol. In some embodiments, the pharmaceutical formulation comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% polyol.
[0044] Exemplary formulations of sub-antibacterial doses of azithromycin and azelaic acid in combination with polyols are shown in Table 5. [Table 5]
[0045] In some instances, it is beneficial to administer a sub-antibacterial dose of azithromycin, a sub-antiparasitic dose of avermectin and / or a dicarboxylic acid (e.g., azelaic acid) together with an immunosuppressant. In this manner, improvement in the quantity and / or quality of meibum can be achieved with azithromycin, avermectin, and / or a dicarboxylic acid (e.g., azelaic acid), and further improvement in the inflammatory aspects of the ocular condition can be achieved simultaneously with the immunosuppressant. The disclosed formulations can be useful in simultaneously treating ADDE and EDE. In some embodiments, the pharmaceutical formulation comprises an immunosuppressant. In some embodiments, the immunosuppressant is selected from the group consisting of cyclosporine, tacrolimus, and lifitegrast. In some embodiments, the immunosuppressant is cyclosporine. In some embodiments, the immunosuppressant is tacrolimus. In some embodiments, the immunosuppressant is lifitegrast. In some embodiments, the pharmaceutical formulation comprises less than about 1% of an immunosuppressant. In some embodiments, the pharmaceutical formulation comprises about 0.01% to about 5% of an immunosuppressant. In some embodiments, the pharmaceutical formulation comprises about 0.01% to about 0.1% of an immunosuppressant. In some embodiments, the pharmaceutical formulation comprises about 0.01% to about 0.05% of an immunosuppressant. In some embodiments, the pharmaceutical formulation comprises about 0.05% to about 0.1% of an immunosuppressant. In some embodiments, the pharmaceutical formulation comprises about 0.1% to about 5% of an immunosuppressant. In some embodiments, the pharmaceutical formulation comprises about 1% of an immunosuppressant. In some embodiments, the pharmaceutical formulation comprises about 5% of an immunosuppressant.
[0046] In some embodiments, the pharmaceutical formulation comprises one or more additional agents selected from the group consisting of brimonidine, isotretinoin, cyclosporine, hypochlorous acid, and tea tree oil.
[0047] Additionally or alternatively, the pharmaceutical formulations disclosed herein may be suitable for treating dermatological conditions, including rosacea and acne, regardless of age (i.e., for all age groups).
[0048] In some embodiments of the pharmaceutical formulations disclosed herein, the formulation may contain one or more additional pharmaceutically acceptable carriers. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described, for example, in "Pharmaceuticals - The Science of Dosage Form Designs" MEAulton, Churchill Livingstone, 1988, the entire contents of which are incorporated herein by reference.
[0049] The term "carrier" as used herein can encompass carriers, excipients, and diluents, and can refer to materials, formulations, or vehicles, such as liquid or solid fillers, diluents, excipients, solvents, or encapsulating materials, that are involved in carrying or transporting pharmaceuticals, such as one or more crystalline forms of the present disclosure, from one organ or part of the body to another organ or part of the body of a subject. Carriers should be selected based on the compatibility and release profile characteristics of the desired dosage form. Exemplary carrier materials can include, for example, binders, suspending agents, disintegrants, fillers, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, spray-dried dispersions, etc. See, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975.
[0050] In some embodiments, the formulations described herein may contain mineral oil and / or petrolatum.
[0051] In some aspects, the agents described herein, alone or as part of a pharmaceutical formulation, are also understood to include any pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. How to Treat the Disorder
[0052] As described above, the formulations disclosed herein can be applied safely and chronically to treat ocular disorders. Unlike commercially available, higher-concentration antibiotic or antiparasitic formulations used for their intended antibiotic or antiparasitic purposes, which can only be applied acutely to the eye or cannot be applied to the eye at all, the present subantibacterial and subantiparasitic formulations, as well as formulations containing dicarboxylic acids (e.g., azelaic acid), directly target the meibomian glands, restoring the natural meibum lipid chemistry and melting temperature, thereby improving the quantity and / or quality of meibum produced and available to chronically coat the outermost lipid layer of tears. The methods described herein can alleviate symptoms of insufficient tear production or poor tear quality. In some embodiments, symptoms of insufficient tear production or poor tear quality can be redness, stinging, burning, itching, light sensitivity, watery eyes, blurred vision, ocular surface irregularities, or damage to the corneal or conjunctival epithelium and tissue. The formulations of the present invention can be safely applied daily for extended periods of time.
[0053] Chronic application can include, for example, applying the disclosed pharmaceutical formulations for a period of at least one month. Notably, the formulations could be applied for significantly longer than one month. For example, the formulations could be applied for at least two months, six months, one year, two years, three years, four years, five years, ten years, or longer. This directly benefits patients suffering from chronic or congenital DED or blepharitis, or patients who otherwise need improved meibum quality, which cannot be achieved with the previously mentioned existing commercially available formulations.
[0054] Specifically, the pharmaceutical formulations disclosed herein may be administered (e.g., applied) daily for at least one month. In some embodiments, the pharmaceutical formulation is administered daily for at least two months. In some embodiments, the pharmaceutical formulation is administered daily for at least three months. In some embodiments, the pharmaceutical formulation is administered daily for at least four months. In some embodiments, the pharmaceutical formulation is administered daily for at least five months. In some embodiments, the pharmaceutical formulation is administered daily for at least six months. In some embodiments, the pharmaceutical formulation is administered daily for at least seven months. In some embodiments, the pharmaceutical formulation is administered daily for at least eight months. In some embodiments, the pharmaceutical formulation is administered daily for at least nine months. In some embodiments, the pharmaceutical formulation is administered daily for at least ten months. In some embodiments, the pharmaceutical formulation is administered daily for at least eleven months. In some embodiments, the pharmaceutical formulation is administered daily for at least one year. In some embodiments, the pharmaceutical formulation is administered daily for at least two years. In some embodiments, the pharmaceutical formulation is administered daily for at least three years. In some embodiments, the pharmaceutical formulation is administered daily for at least 4 months. In some embodiments, the pharmaceutical formulation is administered daily for at least 5 years.
[0055] The pharmaceutical formulations disclosed herein can also be administered every other day. In some embodiments, the pharmaceutical formulations are administered every other week (e.g., one week of administration followed by one week of no administration). In some embodiments, the pharmaceutical formulations are administered every other month.
[0056] In the methods disclosed herein, daily administration of a pharmaceutical formulation can mean once per day (i.e., once a day). In some cases, it may be beneficial to apply the pharmaceutical formulation more than once per day. In these cases, daily can mean twice a day (i.e., twice a day), three times a day, four times a day, or more.
[0057] Generally, the method for treating eye symptoms in a subject who needs to treat eye symptoms can comprise administering one or more compounds or pharmaceutical preparations as described herein.In some embodiments, the method for treating dry eye disease in a subject who needs to treat dry eye disease can comprise administering one or more compounds or pharmaceutical preparations as described herein.In some embodiments, the method for treating blepharitis in a subject who needs to treat blepharitis can comprise administering one or more compounds or pharmaceutical preparations as described herein.
[0058] In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein in the manufacture of a medicament for treating a disorder. In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein in the manufacture of a medicament for treating an ophthalmic condition. In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein in the manufacture of a medicament for treating dry eye disease. In some embodiments, provided herein is the use of one or more pharmaceutical compounds or pharmaceutical formulations described herein in the manufacture of a medicament for treating blepharitis. In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein in the manufacture of a medicament for increasing meibum secretion.
[0059] In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein as a medicament for treating a disorder. In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein as a medicament for treating an ophthalmic condition. In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein as a medicament for treating dry eye disease. In some embodiments, provided herein is the use of one or more pharmaceutical compounds or pharmaceutical formulations described herein as a medicament for treating blepharitis. In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein as a medicament for increasing meibum secretion.
[0060] In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein to treat a disorder. In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein to treat an ocular condition. In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein to treat dry eye disease. In some embodiments, provided herein is the use of one or more pharmaceutical compounds or pharmaceutical formulations described herein to treat blepharitis. In some embodiments, provided herein is the use of one or more compounds or pharmaceutical formulations described herein to increase meibum secretion.
[0061] The methods described herein can be useful in treating any ocular condition in which the amount of meibum produced or the quality of the meibum produced is reduced. Generally, this can be achieved through the application of a sub-antibacterial dose of an antibiotic. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of an antibiotic. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of an antibiotic, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month.
[0062] Similarly, common ocular conditions in which the quantity or quality of meibum is affected can be treated by the methods disclosed herein, where a sub-antiparasitic dose of an antiparasitic agent is applied. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of an antibiotic. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of an antibiotic, where (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month.
[0063] Similarly, common ocular conditions in which the quantity and / or quality of meibum is affected can be treated by the methods disclosed herein, in which a dicarboxylic acid (e.g., azelaic acid) is applied. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a dicarboxylic acid (e.g., azelaic acid). In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a dicarboxylic acid (e.g., azelaic acid), wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month.
[0064] In some embodiments, the antibiotic applied at a sub-antibacterial dose can be azithromycin. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin, wherein: (a) the pharmaceutical formulation is administered to the eyelid; and (b) the pharmaceutical formulation is administered daily for at least one month. In some embodiments, the sub-antibacterial dose of azithromycin can address posterior blepharitis.
[0065] Alternatively, in some embodiments, the antiparasitic drug applied in an antiparasitic dose can be avermectin. In some embodiments, provided herein is a method for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising an antiparasitic dose of avermectin. In some embodiments, provided herein is a method for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising an antiparasitic dose of avermectin, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month. In some embodiments, the antiparasitic dose of avermectin can treat posterior blepharitis.
[0066] A method for treating ocular conditions, comprising administering to a subject a pharmaceutical formulation comprising: a) sub-antibacterial dose of azithromycin; b) sub-antiparasitic dose of avermectin; c) sub-antibacterial dose of azithromycin and sub-antiparasitic dose of avermectin; d) sub-antibacterial dose of azithromycin or sub-antiparasitic dose of avermectin, and an immunosuppressant; e) sub-antibacterial dose of azithromycin or sub-antiparasitic dose of avermectin, and azelaic acid; or f) azelaic acid.In some embodiments, the pharmaceutical formulation is applied to eyelids daily for at least one month.In some embodiments of any of the methods described herein, the ocular condition is one or more of dry eye disease, blepharitis, and meibomian gland dysfunction.
[0067] As described above, DED can be caused by or due to an adversely affected quantity or quality of meibum. Therefore, DED can be treated by the formulations of the present invention through improving the quantity or quality of meibum. In some embodiments, provided herein are methods for treating dry eye disease in a subject in need thereof. In some embodiments, provided herein are methods for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of an antibiotic. In some embodiments, provided herein are methods for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of an antibiotic, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month. In some embodiments, provided herein are methods for treating dry eye disease by lowering the melting temperature of meibum. A method of treating dry eye disease in a subject in need thereof can include administering a pharmaceutical formulation comprising a sub-antibacterial dose of an antibiotic and further comprising a dicarboxylic acid (e.g., azelaic acid).
[0068] Alternatively, but through a similar mechanism, DED can be treated using an antiparasitic drug at a sub-antiparasitic dose. In some embodiments, provided herein is a method for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising an antiparasitic drug at a sub-antiparasitic dose. In some embodiments, provided herein is a method for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising an antiparasitic drug at a sub-antiparasitic dose, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month. The method for treating dry eye disease in a subject in need thereof can comprise administering a pharmaceutical formulation comprising an antiparasitic drug at a sub-antiparasitic dose and a dicarboxylic acid (e.g., azelaic acid).
[0069] In some embodiments, provided herein are methods for treating dry eye disease in a subject in need thereof. In some embodiments, provided herein are methods for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin. In some embodiments, provided herein are methods for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month. The method for treating dry eye disease in a subject in need thereof can comprise administering a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin and a dicarboxylic acid (e.g., azelaic acid).
[0070] In some embodiments, the methods for treating dry eye disease disclosed herein include administering a pharmaceutical formulation described herein to the outer surface of the eyelid of a subject, wherein administering the pharmaceutical formulation alleviates symptoms of dry eye disease. In some embodiments, the symptoms of dry eye disease can be meibomian gland dysfunction, redness, stinging, burning, itching, light sensitivity, watery eyes, blurred vision, ocular surface irregularities, or damage to the epithelium and tissue of the cornea or conjunctiva.
[0071] In some embodiments, provided herein are methods for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin. In some embodiments, provided herein are methods for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month. In some embodiments, the avermectin is ivermectin.
[0072] In some embodiments, provided herein are methods for treating dry eye disease in a subject in need thereof. In some embodiments, provided herein are methods for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a dicarboxylic acid (e.g., azelaic acid). In some embodiments, provided herein are methods for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a dicarboxylic acid (e.g., azelaic acid), wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month.
[0073] The methods for treating dry eye disease described herein can benefit from the alternating administration of two or more pharmaceutical formulations described herein. Thus, in some embodiments, a method for treating dry eye disease in a subject in need thereof comprises alternating administration of a first pharmaceutical formulation and a second pharmaceutical formulation to the eyelid. In some embodiments, the first pharmaceutical formulation comprises a sub-antibacterial dose of azithromycin and is applied daily, and the second pharmaceutical formulation comprises a sub-antiparasitic dose of avermectin and is applied daily. In some embodiments, the first pharmaceutical formulation comprises a sub-antibacterial dose of azithromycin and is applied daily, and the second pharmaceutical formulation comprises a dicarboxylic acid (e.g., azelaic acid) and is applied daily. In some embodiments, the first pharmaceutical formulation comprises a sub-antiparasitic dose of ivermectin and is applied daily, and the second pharmaceutical formulation comprises a dicarboxylic acid (e.g., azelaic acid) and is applied daily.
[0074] The administration of the two pharmaceutical formulations can be alternated daily, weekly, monthly, or every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. In some embodiments, the alternating administration comprises alternating daily administration of the first and second pharmaceutical formulations (e.g., administering the first pharmaceutical formulation to the eyelid on day 1, the second pharmaceutical formulation to the eyelid on day 2, and the first pharmaceutical formulation to the eyelid on day 3, etc.). In some embodiments, the alternating administration comprises alternating monthly administration of the first and second pharmaceutical formulations (e.g., administering the first pharmaceutical formulation to the eyelid as described herein for one month, administering the second pharmaceutical formulation to the eyelid as described herein for the next month, administering the first pharmaceutical formulation to the eyelid as described herein for another month, etc.). In some embodiments, the alternating administration comprises alternating administration of the first and second pharmaceutical formulations every two months.
[0075] As mentioned above, DED can be described as a general term that encompasses several sub-disorders. In some embodiments, the dry eye disease is ADDE. In some embodiments, the dry eye disease is EDE. In some embodiments, the dry eye disease is ADDE and EDE. The methods for treating dry eye disease disclosed herein can simultaneously treat ADDE and EDE.
[0076] DED is sometimes associated with underlying factors. One of these factors may be age. In some embodiments, dry eye disease is associated with biology. In some embodiments, dry eye disease is associated with autoimmune disease. In some embodiments, dry eye disease is associated with medications taken for other indications. In some embodiments, dry eye disease is associated with medical device use. In some embodiments, dry eye disease is associated with contact lenses. In some embodiments, dry eye disease is associated with the environment. In some embodiments, dry eye disease is associated with laser eye surgery. In some embodiments, dry eye disease is associated with cataract surgery. In some embodiments, dry eye disease is associated with smoking. In some embodiments, dry eye disease is associated with excessive use of screens, such as screens on smartphones, computers, tablets, etc. In some embodiments, dry eye disease is associated with mucin deficiency.
[0077] Generally, the methods disclosed herein can include applying a sub-antibacterial dose of an antibiotic useful for treating blepharitis in a subject in need of such treatment.In some embodiments, the present invention provides a method for treating blepharitis in a subject in need of such treatment, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of an antibiotic.In some embodiments, the present invention provides a method for treating blepharitis in a subject in need of such treatment, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of an antibiotic, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month.The method for treating blepharitis in a subject in need of such treatment can include administering a pharmaceutical formulation comprising a sub-antibacterial dose of an antibiotic and further comprising a dicarboxylic acid (e.g., azelaic acid).
[0078] Alternatively, the method for treating blepharitis in a subject in need of treatment can comprise administering to the subject a pharmaceutical preparation comprising an antiparasitic drug at a sub-antiparasitic dose.In some embodiments, the present invention provides a method for treating blepharitis in a subject in need of treatment, comprising administering to the subject a pharmaceutical preparation comprising an antiparasitic drug at a sub-antiparasitic dose, wherein (a) the pharmaceutical preparation is administered to the eyelid, and (b) the pharmaceutical preparation is administered daily for at least one month.The method for treating blepharitis in a subject in need of treatment can comprise administering a pharmaceutical preparation comprising an antiparasitic drug at a sub-antiparasitic dose, and further comprising a dicarboxylic acid (e.g., azelaic acid).
[0079] Furthermore, a method for treating blepharitis in a subject in need thereof can include administering to the subject a pharmaceutical formulation comprising a dicarboxylic acid (e.g., azelaic acid). In some embodiments, provided herein is a method for treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a dicarboxylic acid (e.g., azelaic acid), wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month.
[0080] The method for treating blepharitis described herein can benefit from the alternating administration of two or more pharmaceutical preparations described herein.Thus, in some embodiments, the method for treating blepharitis in a subject who needs to treat blepharitis comprises alternating administration of a first pharmaceutical preparation and a second pharmaceutical preparation to the eyelid.In some embodiments, the first pharmaceutical preparation comprises azithromycin at a sub-antibacterial dose and is applied daily, and the second pharmaceutical preparation comprises avermectin at a sub-antiparasitic dose and is applied daily.In some embodiments, the first pharmaceutical preparation comprises azithromycin at a sub-antibacterial dose and is applied daily, and the second pharmaceutical preparation comprises dicarboxylic acid (e.g., azelaic acid) at a sub-antiparasitic dose and is applied daily. In some embodiments, the first pharmaceutical formulation contains a sub-antiparasitic dose of ivermectin and is applied daily, and the second pharmaceutical formulation contains a sub-antiparasitic dose of a dicarboxylic acid (e.g., azelaic acid) and is applied daily. The administration of the two pharmaceutical formulations can be alternated daily, weekly, monthly, or every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. In some embodiments, the alternating administration comprises alternating daily administration of the first and second pharmaceutical formulations. In some embodiments, the alternating administration comprises alternating monthly administration of the first and second pharmaceutical formulations. In some embodiments, the alternating administration comprises alternating every two months administration of the first and second pharmaceutical formulations.
[0081] In some embodiments, the antibiotic applied at a sub-antibacterial dose to treat blepharitis can be azithromycin. In some embodiments, provided herein are methods for treating blepharitis in a subject in need thereof. In some embodiments, provided herein are methods for treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin. In some embodiments, provided herein are methods for treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month. The method for treating blepharitis in a subject in need thereof can comprise administering a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin and further comprising a dicarboxylic acid (e.g., azelaic acid).
[0082] The methods described herein may be useful for simultaneously treating both anterior and posterior blepharitis. In some embodiments, anterior and posterior blepharitis are treated by administering a single pharmaceutical formulation. In some embodiments, anterior and posterior blepharitis are treated by alternating administration of a first pharmaceutical formulation and a second pharmaceutical formulation. In some embodiments, a dicarboxylic acid (e.g., azelaic acid) treats anterior blepharitis, and a subantibacterial dose of azithromycin treats posterior blepharitis. In some embodiments, the dicarboxylic acid (e.g., azelaic acid) and the subantiparasitic dose of azithromycin are part of a single formulation. In some embodiments, the dicarboxylic acid (e.g., azelaic acid) and the subantibacterial dose of azithromycin are separate formulations.
[0083] Alternatively, the antiparasitic drug applied at a sub-antiparasitic dose to treat blepharitis can be avermectin. In some embodiments, provided herein is a method for treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin. In some embodiments, provided herein is a method for treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month. The method for treating blepharitis in a subject in need thereof can comprise administering a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin and further comprising a dicarboxylic acid (e.g., azelaic acid). In some embodiments, the avermectin is ivermectin.
[0084] The methods described herein can be useful for simultaneously treating both anterior and posterior blepharitis. In some embodiments, anterior and posterior blepharitis are treated by administering a single pharmaceutical formulation. In some embodiments, anterior and posterior blepharitis are treated by alternating administration of a first pharmaceutical formulation and a second pharmaceutical formulation. In some embodiments, a dicarboxylic acid (e.g., azelaic acid) treats anterior blepharitis, and a sub-antiparasitic antiparasitic drug treats posterior blepharitis. In some embodiments, the dicarboxylic acid (e.g., azelaic acid) and the sub-antiparasitic antiparasitic drug are part of a single formulation. In some embodiments, the dicarboxylic acid (e.g., azelaic acid) and the sub-antiparasitic antiparasitic drug are separate formulations.
[0085] As mentioned above, blepharitis can describe several sub-symptoms. In some aspects, the blepharitis is anterior blepharitis. In some aspects, the blepharitis is posterior blepharitis. In some aspects, the blepharitis is both anterior and posterior blepharitis.
[0086] In general, the methods described herein can be useful for increasing meibum secretion. Increased meibum secretion can result from the disclosed formulations improving meibum quantity or quality, for example, by altering lipid chemistry, lowering the melting temperature of meibum, or liquefying hardened meibum. In some embodiments, provided herein are methods for increasing meibum secretion in a subject in need thereof. In some embodiments, provided herein are methods for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of an antibiotic. In some embodiments, provided herein are methods for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of an antibiotic, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month. A method for increasing meibum secretion in a subject in need thereof can include administering a pharmaceutical formulation comprising a sub-antibacterial dose of an antibiotic and further comprising a dicarboxylic acid (e.g., azelaic acid). In some embodiments, the fluidity of meibum is increased. In some embodiments, the melting temperature of meibum is decreased.
[0087] In some embodiments, provided herein are methods for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of an antiparasitic drug. In some embodiments, provided herein are methods for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of an antiparasitic drug, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month. The methods for increasing meibum secretion in a subject in need thereof may comprise administering a sub-antiparasitic dose of an antiparasitic drug, further comprising a dicarboxylic acid (e.g., azelaic acid).
[0088] In some embodiments, provided herein are methods for increasing meibum secretion in a subject in need thereof, the methods comprising administering to the subject a pharmaceutical formulation comprising a dicarboxylic acid (e.g., azelaic acid). In some embodiments, provided herein are methods for increasing meibum secretion in a subject in need thereof, the methods comprising administering to the subject a pharmaceutical formulation comprising a dicarboxylic acid (e.g., azelaic acid), wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month.
[0089] The methods for increasing meibum secretion described herein may benefit from alternating administration of two or more pharmaceutical formulations described herein. Thus, in some embodiments, a method for increasing meibum secretion in a subject in need thereof comprises alternating administration of a first pharmaceutical formulation and a second pharmaceutical formulation to the eyelid. In some embodiments, the first pharmaceutical formulation comprises a sub-antibacterial dose of azithromycin and is applied daily, and the second pharmaceutical formulation comprises a sub-antiparasitic dose of avermectin and is applied daily. In some embodiments, the first pharmaceutical formulation comprises a sub-antibacterial dose of azithromycin and is applied daily, and the second pharmaceutical formulation comprises a sub-antiparasitic dose of a dicarboxylic acid (e.g., azelaic acid) and is applied daily. In some embodiments, the first pharmaceutical formulation comprises a sub-antiparasitic dose of ivermectin and is applied daily, and the second pharmaceutical formulation comprises a sub-antiparasitic dose of a dicarboxylic acid (e.g., azelaic acid) and is applied daily. The administration of the two pharmaceutical formulations can be alternated daily, weekly, monthly, or every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. In some embodiments, the alternating administration comprises alternating daily administration of the first and second pharmaceutical formulations. In some embodiments, the alternating administration comprises alternating monthly administration of the first and second pharmaceutical formulations. In some embodiments, the alternating administration comprises alternating every two months administration of the first and second pharmaceutical formulations.
[0090] In some embodiments, the antibiotic applied at a sub-antibacterial dose to increase meibum secretion can be azithromycin. In some embodiments, provided herein are methods for increasing meibum secretion in a subject in need thereof. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin. In some embodiments, provided herein are methods for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin, wherein: (a) the pharmaceutical formulation is administered to the eyelid; and (b) the pharmaceutical formulation is administered daily for at least one month. The method for increasing meibum secretion in a subject in need thereof can include administering a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin and further comprising a dicarboxylic acid (e.g., azelaic acid).
[0091] Alternatively, the antiparasitic drug applied at a sub-antiparasitic dose to increase meibum production can be avermectin. In some embodiments, provided herein are methods for treating an ocular condition in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin. In some embodiments, provided herein are methods for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin, wherein (a) the pharmaceutical formulation is administered to the eyelid, and (b) the pharmaceutical formulation is administered daily for at least one month. The method for increasing meibum secretion in a subject in need thereof can include administering a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin and further comprising a dicarboxylic acid (e.g., azelaic acid). In some embodiments, the avermectin is ivermectin.
[0092] The mechanisms of action of the formulations and methods described herein, as discussed above, are premised on a different mechanism of action than those typically contemplated by the use of chemical agents (i.e., treating bacterial or parasitic infections, treating inflammation). Subjects who would benefit from the disclosed formulations and methods may not have a bacterial ocular infection. In some embodiments, subjects in need of the disclosed formulations and methods do not have a parasitic ocular infection. In some embodiments, subjects in need of the disclosed formulations and methods do not have a bacterial ocular infection and do not have a parasitic ocular infection. In some embodiments, subjects in need of the disclosed formulations and methods do not have a clinically diagnosable parasitic ocular infection. In some embodiments, subjects in need of the disclosed formulations and methods do not have a clinically diagnosable parasitic ocular infection. In this context, "clinically diagnosable" means that the parasitic or bacterial infection results in symptoms of infection and is distinguishable from asymptomatic surface colonization.
[0093] Because the pharmaceutical formulations described herein increase the quality or quantity of meibum, they may be useful in enhancing the safety or effectiveness of existing treatments (e.g., compression, home hot compresses, energy-based devices in clinics) or in addressing deficiencies in existing treatments. In some embodiments, provided herein are methods for enhancing the safety and effectiveness of currently available DED treatments. In some embodiments, provided herein are methods for enhancing the safety and effectiveness of currently available MGD treatments. In some embodiments, the pharmaceutical formulations described herein can be used before using an existing treatment for dry eye disease. In some embodiments, provided herein are methods for using an existing treatment (e.g., heat-based therapy) in combination with the methods and formulations described herein. For example, an existing treatment can be used before, simultaneously with, or after any of the methods disclosed herein.
[0094] The pharmaceutical formulation of any of the methods described herein can be administered to the eyelid. In some embodiments, the pharmaceutical formulation is administered directly to the outer (e.g., external) surface of the eyelid (e.g., the outer skin of the eyelid, above the eyelid margin, above the upper eyelashes, or below the lower eyelashes). In some embodiments, the pharmaceutical formulation is administered to the skin of the eyelid, but not to the eyelid margin. In some embodiments, the formulation can penetrate the skin of the eyelid and be delivered to one or more meibomian glands. In some embodiments, the pharmaceutical formulation is administered directly to the eyelid margin. In some embodiments, the pharmaceutical formulation is administered indirectly to the eyelid. In some embodiments, the pharmaceutical formulation is applied to the surface of the eye and contacts the inner surface of the eyelid, thereby indirectly administering to the eyelid. In some embodiments, the pharmaceutical formulation is applied to the surface of the eye and contacts the eyelid margin, thereby indirectly administering to the eyelid. In some embodiments, the pharmaceutical formulation is administered to the eyelid via an ocular insert.
[0095] The application of the pharmaceutical formulation of the method disclosed herein can be achieved by administration via any route suitable for delivery to the eye.For example, it may be useful to apply the pharmaceutical formulation via a dropper.In some embodiments, the formulation can be applied via an applicator stick.In some embodiments, the formulation can be applied by finger.In some embodiments, the formulation can be applied via an ocular insert.In some embodiments, the pharmaceutical formulation can be rolled on or sprayed on.
[0096] As described above, the methods and formulations described herein may be suitable for treating one or more ocular conditions, where an improvement in one or more symptoms of the ocular condition is observed. This improvement may be quantified in several ways. For example, the methods and formulations described herein may result in reduced matrix metalloproteinase (e.g., MMP9) activity in tears or secretions. In some embodiments, matrix metalloproteinase activity may be reduced by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80%. In certain embodiments, the methods and formulations described herein may result in more liquefied meibum, as quantified by an increased meibomian gland secretion score. In some embodiments, the meibomian gland secretion score may be increased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, or 400%. In some embodiments, the methods and formulations described herein can result in increased lipid layer thickness, for example, as measured by lipid layer interferometry. In some embodiments, the lipid layer thickness can be increased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or 200%. In some embodiments, the methods and formulations described herein can result in increased tear film breakup time (TBUT). In some embodiments, TBUT can be increased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, or 400%. In certain embodiments, the methods and formulations described herein may result in fewer symptoms reported by patients in subjective questionnaires (e.g., Standard Patient Evaluation of Eye Dryness (SPEED); Ocular Surface Disease Index (OSDI); Symptom Assessment Questionnaire in Dry Eye (SANDE)).For example, the methods and formulations may reduce SPEED symptoms, OSDI symptoms, SANDE symptoms, and / or dry eye score symptoms. In some embodiments, symptoms may be reduced by at least 5%, 10%, 20%, 30%, 40%, or 50%. In certain embodiments, the methods and formulations described herein may result in reduced damage to the ocular surface as assessed by corneal and conjunctival staining. For example, the methods and formulations described herein may result in reduced staining of the cornea and / or conjunctiva. In some embodiments, staining may be reduced by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. In certain embodiments, the methods and formulations described herein may result in a reduction in the number of blocked, occluded, and / or keratinized meibomian glands. In some embodiments, the number of blocked, occluded, and / or keratinized meibomian glands can be reduced by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. In some embodiments, the methods and formulations described herein can result in reduced tear osmolality. In some embodiments, tear osmolality can be reduced by at least 5%, 10%, 20%, 30%, 40%, or 50%. In some embodiments, the methods and formulations described herein can result in reduced Demodex folliculorum counts.
[0097] The methods and formulations described herein can result in improved visual acuity. In some embodiments, the methods and formulations described herein can result in improved contact lens wear (e.g., less wear). In some embodiments, the methods and formulations described herein can result in improved reading speed. In some embodiments, the methods and formulations described herein can improve the outcome of cataract surgery by improving the accuracy of preoperative measurements through improved tear film quality.
[0098] In some embodiments of the methods and formulations described herein, improvement in one or more of the above symptoms of the ocular condition can be observed over a period of about one week to about one year or more after initiating application of the formulation, or when measured from about one week to about one year or more after initiating application of the formulation. In some embodiments, improvement can be observed after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 weeks. In certain embodiments, improvement can be observed after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 months. In some embodiments, improvement may be observed between 1 month and 24 months, between 1 month and 18 months, between 1 month and 12 months, between 1 month and 6 months, between 1 month and 2 months, between 2 months and 4 months, between 2 months and 6 months, between 2 months and 12 months, between 2 months and 18 months, between 2 months and 24 months, between 3 months and 24 months, between 3 months and 18 months, between 3 months and 12 months, between 6 months and 24 months, between 6 months and 18 months, between 6 months and 12 months, between 12 months and 24 months, between 12 months and 18 months, or between 18 months and 24 months. kit
[0099] In some embodiments, the present disclosure also provides pharmaceutical packages or kits comprising one or more containers filled with at least one pharmaceutical formulation of the present disclosure. Optionally, such containers may be accompanied by an applicator for the formulation. The applicator may be, for example, a dropper, an applicator stick, or an eye insert. Optionally, such containers may further be accompanied by a notice in a form prescribed by a government agency regulating the manufacture, use, or sale of pharmaceutical or biological products, which notice reflects (a) approval by the agency of manufacture, use, or sale for human administration, (b) instructions for use, or both. Instructions for use may also be provided.
[0100] In some embodiments, the pharmaceutical package or kit may include a thermal therapy device (eg, TearCare®).
[0101] The foregoing applies to any of the pharmaceutical formulations, methods, and uses described herein. The present disclosure specifically contemplates any combination of the features of such pharmaceutical formulations, methods, and uses (alone or in combination) with the features described for the various kits described in this section.
[0102] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, exemplary methods and materials are described herein. Other features, objects, and advantages of the present disclosure will be apparent from the description and claims. In this specification and the appended claims, the singular forms "a," "an," and "the" include the plural forms unless the context clearly dictates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.
[0103] Each aspect described herein may be taken alone or in combination with any one or more other aspects. Exemplary Embodiments
[0104] Embodiment I-1. A method for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0105] Embodiment I-2. A method for treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0106] Embodiment I-3. A method for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0107] Embodiment I-4. A method for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0108] Embodiment I-5. A method for treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0109] Embodiment I-6. A method for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0110] Embodiment I-7. The method of any one of embodiments I-4 to I-6, wherein the avermectin is ivermectin.
[0111] Embodiment I-8. The method of any one of embodiments I-1 to I-7, wherein the subject in need thereof does not have an ocular bacterial infection.
[0112] Embodiment I-9. The method of any one of embodiments I-1 to I-7, wherein the subject in need thereof does not have an eye parasitic infection.
[0113] Embodiment I-10. The method of any one of embodiments I-1 to I-3 or I-8 to I-9, wherein the pharmaceutical formulation further comprises an avermectin.
[0114] Embodiment I-11. The method of any one of embodiments I-4 to I-10, wherein the pharmaceutical formulation further comprises azithromycin.
[0115] Embodiment I-12. The method of any one of Embodiments I-1 to I-11, wherein the pharmaceutical formulation further comprises at least one skin penetration enhancer.
[0116] Embodiment I-13. The method of any one of embodiments I-1 to I-12, wherein the pharmaceutical formulation further comprises an immunosuppressant.
[0117] Embodiment I-14. The method of embodiment I-13, wherein the immunosuppressant is selected from the group consisting of cyclosporine, tacrolimus, and lifitegrast.
[0118] Embodiment I-15. The method of any one of embodiments I-1 through I-3, I-8 through I-10, or I-12 through I-14, wherein the pharmaceutical formulation comprises less than 1% w / v azithromycin.
[0119] Embodiment I-16. The method of any one of embodiments I-1 through I-3, I-8 through I-10, or I-12 through I-14, wherein the pharmaceutical formulation comprises 0.5% w / v or less azithromycin.
[0120] Embodiment I-17. The method of any one of embodiments I-1 through I-3, I-8 through I-10, or I-12 through I-14, wherein the pharmaceutical formulation comprises 0.1% w / v or less azithromycin.
[0121] Embodiment I-18. The method of any one of embodiments I-1 through I-3, I-8 through I-10, or I-12 through I-14, wherein the pharmaceutical formulation comprises 0.01% w / v or less azithromycin.
[0122] Embodiment I-19. The method of any one of embodiments I-4 to I-9 or I-11 to I-14, wherein the pharmaceutical formulation comprises less than 1% w / v avermectin.
[0123] Embodiment I-20. The method of any one of embodiments I-4 through I-9 or I-11 through I-14, wherein the pharmaceutical formulation comprises 0.5% w / v or less of avermectin.
[0124] Embodiment I-21. The method of any one of embodiments I-4 through I-9 or I-11 through I-14, wherein the pharmaceutical formulation comprises 0.1% w / v or less of avermectin.
[0125] Embodiment I-22. The method of any one of embodiments I-4 through I-9 or I-11 through I-14, wherein the pharmaceutical formulation comprises 0.01% w / v or less of avermectin.
[0126] Embodiment I-23. The method of any one of embodiments I-1 to I-22, wherein the pharmaceutical formulation is administered daily for two months.
[0127] Embodiment I-24. The method of any one of embodiments I-1 to I-22, wherein the pharmaceutical formulation is administered daily for six months.
[0128] Embodiment I-25. The method of any one of embodiments I-1 to I-10, wherein the pharmaceutical formulation is applied daily for at least one year.
[0129] Embodiment I-26. The method of any one of Embodiments I-1 to I-25, wherein the pharmaceutical formulation is applied as a cream, gel, suspension, solution, ointment, or spray.
[0130] Embodiment I-27. The method of any one of Embodiments I-1 to I-25, wherein the pharmaceutical formulation is applied as drops.
[0131] Embodiment I-28. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antibacterial dose of azithromycin.
[0132] Embodiment I-29. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antiparasitic dose of avermectin.
[0133] Embodiment I-30. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antibacterial dose of azithromycin and a sub-antiparasitic dose of avermectin.
[0134] Embodiment I-31. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antibacterial dose of azithromycin or a sub-antiparasitic dose of avermectin, and further comprising an immunosuppressant.
[0135] Embodiment II-1. A method for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0136] Embodiment II-2. A method for treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0137] Embodiment II-3. A method for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0138] Embodiment II-4. A method for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0139] Embodiment II-5. A method for treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0140] Embodiment II-6. A method for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0141] Embodiment II-7. The method of any one of Embodiments II-4 to II-6, wherein the avermectin is ivermectin.
[0142] Embodiment II-8. The method of any one of embodiments II-1 to II-7, wherein the subject in need thereof does not have an ocular bacterial infection.
[0143] Embodiment II-9. The method of any one of embodiments II-1 to II-7, wherein the subject in need thereof does not have an eye parasitic infection.
[0144] Embodiment II-10. The method of any one of embodiments II-1 to II-3 or II-8 to II-9, wherein the pharmaceutical formulation further comprises an avermectin.
[0145] Embodiment II-11. The method of any one of Embodiments II-4 to II-10, wherein the pharmaceutical formulation further comprises azithromycin.
[0146] Embodiment II-12. The method of any one of Embodiments II-1 to II-11, wherein the pharmaceutical formulation further comprises at least one skin penetration enhancer.
[0147] Embodiment II-13. The method of any one of embodiments II-1 to II-12, wherein the pharmaceutical formulation further comprises an immunosuppressant.
[0148] Embodiment II-14. The method of embodiment II-13, wherein the immunosuppressant is selected from the group consisting of cyclosporine, tacrolimus, and lifitegrast.
[0149] Embodiment II-15. The method of any one of Embodiments II-1 to II-3, II-8 to II-10, or II-12 to II-14, wherein the pharmaceutical formulation comprises less than 1% w / v azithromycin.
[0150] Embodiment II-16. The method of any one of Embodiments II-1 to II-3, II-8 to II-10, or II-12 to II-14, wherein the pharmaceutical formulation comprises 0.5% w / v or less azithromycin.
[0151] Embodiment II-17. The method of any one of Embodiments II-1 to II-3, II-8 to II-10, or II-12 to II-14, wherein the pharmaceutical formulation comprises 0.1% w / v or less azithromycin.
[0152] Embodiment II-18. The method of any one of Embodiments II-1 to II-3, II-8 to II-10, or II-12 to II-14, wherein the pharmaceutical formulation comprises 0.01% w / v or less azithromycin.
[0153] Embodiment II-19. The method of any one of embodiments II-4 to II-9 or II-11 to II-14, wherein the pharmaceutical formulation comprises less than 1% w / v avermectin.
[0154] Embodiment II-20. The method of any one of embodiments II-4 to II-9 or II-11 to II-14, wherein the pharmaceutical formulation comprises 0.5% w / v or less of avermectin.
[0155] Embodiment II-21. The method of any one of embodiments II-4 to II-9 or II-11 to II-14, wherein the pharmaceutical formulation comprises 0.1% w / v or less of avermectin.
[0156] Embodiment II-22. The method of any one of embodiments II-4 to II-9 or II-11 to II-14, wherein the pharmaceutical formulation comprises 0.01% w / v or less of avermectin.
[0157] Embodiment II-23. The method of any one of Embodiments II-1 to II-22, wherein the pharmaceutical formulation is administered daily for two months.
[0158] Embodiment II-24. The method of any one of Embodiments II-1 to II-22, wherein the pharmaceutical formulation is administered daily for 6 months.
[0159] Embodiment II-25. The method of any one of Embodiments II-1 to II-10, wherein the pharmaceutical formulation is applied daily for at least one year.
[0160] Embodiment II-26. The method of any one of Embodiments II-1 to II-25, wherein the pharmaceutical formulation is applied as a cream, gel, suspension, solution, ointment, or spray.
[0161] Embodiment II-27. The method of any one of Embodiments II-1 to II-25, wherein the pharmaceutical formulation is applied as drops.
[0162] Embodiment II-28. The method of any one of Embodiments II-1 to II-27, wherein the pharmaceutical formulation further comprises azelaic acid.
[0163] Embodiment II-29. The method of embodiment II-28, wherein the concentration of azelaic acid is about 1% to about 20%.
[0164] Embodiment II-30. The method of any one of embodiments II-28 to II-29, wherein the concentration of azelaic acid is about 10% to about 15%.
[0165] Embodiment II-31. The method of any one of Embodiments II-28 to II-30, wherein the pharmaceutical formulation comprises about 10% to about 20% azelaic acid and about 0.4% to about 0.5% azithromycin.
[0166] Embodiment II-32. The method of any one of Embodiments II-1 to II-31, further comprising at least one of mineral oil, petrolatum, propylene glycol, and polyethylene glycol.
[0167] Embodiment II-33. A method for treating dry eye disease in a subject in need thereof, comprising: the alternating administration of a first pharmaceutical formulation and a second pharmaceutical formulation to the eyelid; a) the first pharmaceutical formulation comprises a sub-antibacterial dose of azithromycin and is applied daily; b) The method wherein said second pharmaceutical formulation comprises a sub-antiparasitic dose of avermectin and is applied daily.
[0168] Embodiment II-34. A method for treating blepharitis in a subject in need thereof, comprising: the alternating administration of a first pharmaceutical formulation and a second pharmaceutical formulation to the eyelid; a) the first pharmaceutical formulation comprises a sub-antibacterial dose of azithromycin and is applied daily; b) The method wherein said second pharmaceutical formulation comprises a sub-antiparasitic dose of avermectin and is applied daily.
[0169] Embodiment II-35. A method for increasing meibum secretion in a subject in need thereof, comprising: the alternating administration of a first pharmaceutical formulation and a second pharmaceutical formulation to the eyelid; a) the first pharmaceutical formulation comprises a sub-antibacterial dose of azithromycin and is applied daily; b) The method wherein said second pharmaceutical formulation comprises a sub-antiparasitic dose of avermectin and is applied daily.
[0170] Embodiment II-36. The method of any one of Embodiments II-33 to II-35, wherein the alternating administration comprises alternating the first and second pharmaceutical formulations daily.
[0171] Embodiment II-37. The method of any one of Embodiments II-33 to II-35, wherein the alternating administration comprises alternating the first and second pharmaceutical formulations monthly.
[0172] Embodiment II-38. The method of any one of Embodiments II-33 to II-35, wherein the alternating administration comprises alternating the first and second pharmaceutical formulations every two months.
[0173] Embodiment II-39. The method of any one of Embodiments II-33 to II-38, wherein the avermectin is ivermectin.
[0174] Embodiment II-40. The method of any one of Embodiments II-33 to II-39, wherein the subject in need thereof does not have an ocular bacterial infection.
[0175] Embodiment II-41. The method of any one of Embodiments II-33 to II-40, wherein the subject in need thereof does not have an eye parasitic infection.
[0176] Embodiment II-42. The method of any one of Embodiments II-33 to II-41, wherein the pharmaceutical formulation further comprises at least one skin penetration enhancer.
[0177] Embodiment II-43. The method of any one of Embodiments II-33 to II-42, wherein the pharmaceutical formulation further comprises an immunosuppressant.
[0178] Embodiment II-44. The method of embodiment II-43, wherein the immunosuppressant is selected from the group consisting of cyclosporine, tacrolimus, and lifitegrast.
[0179] Embodiment II-45. The method of any one of Embodiments II-33 to II-44, wherein the first pharmaceutical formulation comprises less than 1% w / v azithromycin.
[0180] Embodiment II-46. The method of any one of Embodiments II-33 to II-45, wherein the first pharmaceutical formulation comprises 0.5% w / v or less azithromycin.
[0181] Embodiment II-47. The method of any one of Embodiments II-33 to II-46, wherein the first pharmaceutical formulation comprises 0.1% w / v or less azithromycin.
[0182] Embodiment II-48. The method of any one of Embodiments II-33 to II-47, wherein the first pharmaceutical formulation comprises 0.01% w / v or less azithromycin.
[0183] Embodiment II-49. The method of any one of Embodiments II-33 to II-48, wherein the second pharmaceutical formulation comprises less than 1% w / v avermectin.
[0184] Embodiment II-50. The method of any one of Embodiments II-33 to II-49, wherein the second pharmaceutical formulation comprises 0.5% w / v or less of an avermectin.
[0185] Embodiment II-51. The method of any one of Embodiments II-33 to II-50, wherein the second pharmaceutical formulation comprises 0.1% w / v or less of an avermectin.
[0186] Embodiment II-52. The method of any one of Embodiments II-33 to II-51, wherein the second pharmaceutical formulation comprises 0.01% w / v or less of avermectin.
[0187] Embodiment II-53. The method of any one of Embodiments II-33 to II-52, wherein each of the first pharmaceutical formulation and the second pharmaceutical formulation is applied as one of a cream, gel, suspension, solution, ointment, or spray.
[0188] Embodiment II-54. The method of any one of Embodiments II-33 to II-52, wherein the first pharmaceutical formulation and the second pharmaceutical formulation are applied as drops.
[0189] Embodiment II-55. A method of treating dry eye disease or blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising azelaic acid; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0190] Embodiment II-56. A method of treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising azelaic acid; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0191] Embodiment II-57. A method of increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising azelaic acid; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0192] Embodiment II-58. The method of any one of Embodiments II-55 to II-57, wherein the pharmaceutical formulation is administered once daily.
[0193] Embodiment II-59. The method of any one of Embodiments II-55 to II-57, wherein the pharmaceutical formulation is administered twice daily.
[0194] Embodiment II-60. The method of any one of Embodiments II-55 to II-59, wherein the concentration of azelaic acid is about 1% to about 20%.
[0195] Embodiment II-61. The method of any one of Embodiments II-55 to II-60, wherein the concentration of azelaic acid is about 10% to about 15%.
[0196] Embodiment II-62. The method of any one of Embodiments II-55 to II-61, wherein the pharmaceutical formulation further comprises at least one skin penetration enhancer.
[0197] Embodiment II-63. The method of any one of Embodiments II-55 to II-62, wherein the pharmaceutical formulation is administered daily for at least two months.
[0198] Embodiment II-64. The method of any one of Embodiments II-55 to II-63, wherein the pharmaceutical formulation is administered daily for at least 6 months.
[0199] Embodiment II-65. The method of any one of Embodiments II-55 to II-64, wherein the pharmaceutical formulation is administered daily for at least one year.
[0200] Embodiment II-66. The method of any one of Embodiments II-55 to II-65, wherein the pharmaceutical formulation is applied as a cream, gel, suspension, solution, ointment, or spray.
[0201] Embodiment II-67. The method of any one of Embodiments II-55 to II-65, wherein the pharmaceutical formulation is applied as drops.
[0202] Embodiment II-68. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antibacterial dose of azithromycin.
[0203] Embodiment II-69. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antiparasitic dose of avermectin.
[0204] Embodiment II-70. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antibacterial dose of azithromycin and a sub-antiparasitic dose of avermectin.
[0205] Embodiment II-71. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antibacterial dose of azithromycin or a sub-antiparasitic dose of avermectin, and further comprising an immunosuppressant.
[0206] Embodiment II-72. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antibacterial dose of azithromycin or a sub-antiparasitic dose of avermectin, and further comprising azelaic acid.
[0207] Embodiment II-73. The pharmaceutical formulation of embodiment II-72, comprising about 0.4%-0.5% azithromycin and about 10%-15% azelaic acid.
[0208] Embodiment II-74. A pharmaceutical formulation for treating an ophthalmic condition, comprising azelaic acid.
[0209] Embodiment II-75. The pharmaceutical formulation of embodiment II-74, comprising about 10% to 15% azelaic acid.
[0210] Embodiment II-76. A method for treating dry eye disease, treating blepharitis, or increasing meibum secretion in a subject in need thereof, comprising: a) about 5% to about 15% azelaic acid, and b) about 0.4% to about 0.5% azithromycin to the eyelid of the subject, The method wherein the pharmaceutical formulation is administered daily for at least one month.
[0211] Embodiment II-77. The method of any one of embodiments II-2, II-5, II-34, II-55, or II-76, wherein the blepharitis is caused by Demodex mites.
[0212] Embodiment II-78. The method of embodiment II-76, wherein the azelaic acid addresses anterior blepharitis and the azithromycin addresses posterior blepharitis.
[0213] Embodiment II-79. The pharmaceutical formulation of embodiment II-74 or II-75, wherein the azelaic acid treats anterior blepharitis.
[0214] Embodiment II-80. A method for treating an ophthalmic condition, comprising: a) Azithromycin at subantibacterial doses; b) subantiparasitic doses of avermectin; c) subantibacterial doses of azithromycin and subantiparasitic doses of avermectin; d) further comprising a sub-antibacterial dose of azithromycin or a sub-antiparasitic dose of avermectin, and an immunosuppressant; e) further comprising a sub-antibacterial dose of azithromycin or a sub-antiparasitic dose of avermectin, and azelaic acid; or f) azelaic acid; administering to a subject a pharmaceutical formulation comprising The pharmaceutical formulation is applied to the eyelid daily for at least one month.
[0215] Embodiment II-81. The method of embodiment II-80, wherein the ophthalmic condition is one or more of dry eye disease, blepharitis, and meibomian gland dysfunction.
[0216] Embodiment II-82. The pharmaceutical formulation of any one of Embodiments II-68 to II-75, wherein the ophthalmic condition is one or more of dry eye disease, blepharitis, and meibomian gland dysfunction.
[0217] Embodiment III-1. A method for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0218] Embodiment III-2. A method for treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0219] Embodiment III-3. A method for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antibacterial dose of azithromycin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0220] Embodiment III-4. A method for treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0221] Embodiment III-5. A method for treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0222] Embodiment III-6. A method for increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising a sub-antiparasitic dose of avermectin; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0223] Embodiment III-7. The method of any one of embodiments III-4 to III-6, wherein the avermectin is ivermectin.
[0224] Embodiment III-8. The method of any one of embodiments III-1 to III-7, wherein the subject in need thereof does not have an ocular bacterial infection.
[0225] Embodiment III-9. The method of any one of embodiments III-1 to III-7, wherein the subject in need thereof does not have an eye parasitic infection.
[0226] Embodiment III-10. The method of any one of embodiments III-1 to III-3 or III-8 to III-9, wherein the pharmaceutical formulation further comprises an avermectin.
[0227] Embodiment III-11. The method of any one of embodiments III-4 to III-10, wherein the pharmaceutical formulation further comprises azithromycin.
[0228] Embodiment III-12. The method of any one of Embodiments III-1 to III-11, wherein the pharmaceutical formulation further comprises at least one skin penetration enhancer.
[0229] Embodiment III-13. The method of any one of embodiments III-1 to III-12, wherein the pharmaceutical formulation further comprises an immunosuppressant.
[0230] Embodiment III-14. The method of embodiment III-13, wherein the immunosuppressant is selected from the group consisting of cyclosporine, tacrolimus, and lifitegrast.
[0231] Embodiment III-15. The method of any one of embodiments III-1 to III-3, III-8 to III-10, or III-12 to III-14, wherein the pharmaceutical formulation comprises less than 1% w / v azithromycin.
[0232] Embodiment III-16. The method of any one of Embodiments III-1 to III-3, III-8 to III-10, or III-12 to III-14, wherein the pharmaceutical formulation comprises 0.5% w / v or less azithromycin.
[0233] Embodiment III-17. The method of any one of Embodiments III-1 to III-3, III-8 to III-10, or III-12 to III-14, wherein the pharmaceutical formulation comprises 0.1% w / v or less azithromycin.
[0234] Embodiment III-18. The method of any one of Embodiments III-1 to III-3, III-8 to III-10, or III-12 to III-14, wherein the pharmaceutical formulation comprises 0.01% w / v or less azithromycin.
[0235] Embodiment III-19. The method of any one of embodiments III-4 to III-9 or III-11 to III-14, wherein the pharmaceutical formulation comprises less than 1% w / v avermectin.
[0236] Embodiment III-20. The method of any one of embodiments III-4 to III-9 or III-11 to III-14, wherein the pharmaceutical formulation comprises 0.5% w / v or less of avermectin.
[0237] Embodiment III-21. The method of any one of embodiments III-4 to III-9 or III-11 to III-14, wherein the pharmaceutical formulation comprises 0.1% w / v or less of avermectin.
[0238] Embodiment III-22. The method of any one of embodiments III-4 to III-9 or III-11 to III-14, wherein the pharmaceutical formulation comprises 0.01% w / v or less of avermectin.
[0239] Embodiment III-23. The method of any one of embodiments III-1 to III-22, wherein the pharmaceutical formulation is administered daily for two months.
[0240] Embodiment III-24. The method of any one of embodiments III-1 to III-22, wherein the pharmaceutical formulation is administered daily for 6 months.
[0241] Embodiment III-25. The method of any one of Embodiments III-1 to III-10, wherein the pharmaceutical formulation is administered daily for at least one year.
[0242] Embodiment III-26. The method of any one of Embodiments III-1 to III-25, wherein the pharmaceutical formulation is administered as a cream, gel, suspension, solution, ointment, or spray.
[0243] Embodiment III-27. The method of any one of Embodiments III-1 to III-25, wherein the pharmaceutical formulation is administered as drops.
[0244] Embodiment III-28. The method of any one of Embodiments III-1 to III-27, wherein the pharmaceutical formulation further comprises azelaic acid.
[0245] Embodiment III-29. The method of embodiment III-28, wherein the concentration of azelaic acid is about 1% to about 20%.
[0246] Embodiment III-30. The method of any one of embodiments III-28 to III-29, wherein the concentration of azelaic acid is about 10% to about 15%.
[0247] Embodiment III-31. The method of any one of embodiments III-28 to III-30, wherein the pharmaceutical formulation comprises about 10% to about 20% azelaic acid and about 0.4% to about 0.5% azithromycin.
[0248] Embodiment III-32. The method of any one of Embodiments III-1 to III-31, further comprising at least one of mineral oil, petrolatum, propylene glycol, and polyethylene glycol.
[0249] Embodiment III-33. A method for treating dry eye disease in a subject in need thereof, comprising: the alternating administration of a first pharmaceutical formulation and a second pharmaceutical formulation to the eyelid; a) the first pharmaceutical formulation comprises a sub-antibacterial dose of azithromycin and is administered daily; b) The method wherein said second pharmaceutical formulation comprises a sub-antiparasitic dose of avermectin and is administered daily.
[0250] Embodiment III-34. A method for treating blepharitis in a subject in need thereof, comprising: the alternating administration of a first pharmaceutical formulation and a second pharmaceutical formulation to the eyelid; a) the first pharmaceutical formulation comprises a sub-antibacterial dose of azithromycin and is administered daily; b) The method wherein said second pharmaceutical formulation comprises a sub-antiparasitic dose of avermectin and is administered daily.
[0251] Embodiment III-35. A method for increasing meibum secretion in a subject in need thereof, comprising: the alternating administration of a first pharmaceutical formulation and a second pharmaceutical formulation to the eyelid; a) the first pharmaceutical formulation comprises a sub-antibacterial dose of azithromycin and is administered daily; b) The method wherein said second pharmaceutical formulation comprises a sub-antiparasitic dose of avermectin and is administered daily.
[0252] Embodiment III-36. The method of any one of Embodiments III-33 to III-35, wherein the alternating administration comprises alternating the first and second pharmaceutical formulations daily.
[0253] Embodiment III-37. The method of any one of Embodiments III-33 to III-35, wherein the alternating administration comprises alternating the first and second pharmaceutical formulations monthly.
[0254] Embodiment III-38. The method of any one of embodiments III-33 to III-35, wherein the alternating administration comprises alternating the first and second pharmaceutical formulations every two months.
[0255] Embodiment III-39. The method of any one of Embodiments III-33 to III-38, wherein the avermectin is ivermectin.
[0256] Embodiment III-40. The method of any one of embodiments III-33 to III-39, wherein the subject in need thereof does not have an ocular bacterial infection.
[0257] Embodiment III-41. The method of any one of embodiments III-33 to III-40, wherein the subject in need thereof does not have an eye parasitic infection.
[0258] Embodiment III-42. The method of any one of Embodiments III-33 to III-41, wherein the pharmaceutical formulation further comprises at least one skin penetration enhancer.
[0259] Embodiment III-43. The method of any one of embodiments III-33 to III-42, wherein the pharmaceutical formulation further comprises an immunosuppressant.
[0260] Embodiment III-44. The method of embodiment III-43, wherein the immunosuppressant is selected from the group consisting of cyclosporine, tacrolimus, and lifitegrast.
[0261] Embodiment III-45. The method of any one of Embodiments III-33 to III-44, wherein the first pharmaceutical formulation comprises less than 1% w / v azithromycin.
[0262] Embodiment III-46. The method of any one of Embodiments III-33 to III-45, wherein the first pharmaceutical formulation comprises 0.5% w / v or less azithromycin.
[0263] Embodiment III-47. The method of any one of Embodiments III-33 to III-46, wherein the first pharmaceutical formulation comprises 0.1% w / v or less azithromycin.
[0264] Embodiment III-48. The method of any one of Embodiments III-33 to III-47, wherein the first pharmaceutical formulation comprises 0.01% w / v or less azithromycin.
[0265] Embodiment III-49. The method of any one of Embodiments III-33 to III-48, wherein the second pharmaceutical formulation comprises less than 1% w / v avermectin.
[0266] Embodiment III-50. The method of any one of Embodiments III-33 to III-49, wherein the second pharmaceutical formulation comprises 0.5% w / v or less of an avermectin.
[0267] Embodiment III-51. The method of any one of Embodiments III-33 to III-50, wherein the second pharmaceutical formulation comprises 0.1% w / v or less of avermectin.
[0268] Embodiment III-52. The method of any one of embodiments III-33 to III-51, wherein the second pharmaceutical formulation comprises 0.01% w / v or less of avermectin.
[0269] Embodiment III-53. The method of any one of embodiments III-33 to III-52, wherein each of the first pharmaceutical formulation and the second pharmaceutical formulation is administered as one of a cream, gel, suspension, solution, ointment, or spray.
[0270] Embodiment III-54. The method of any one of Embodiments III-33 to III-52, wherein the first pharmaceutical formulation and the second pharmaceutical formulation are administered as drops.
[0271] Embodiment III-55. A method of treating dry eye disease in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising azelaic acid; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0272] Embodiment III-56. A method of treating blepharitis in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising azelaic acid; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0273] Embodiment III-57. A method of increasing meibum secretion in a subject in need thereof, comprising administering to the subject a pharmaceutical formulation comprising azelaic acid; a) the pharmaceutical formulation is administered to the eyelid; b) The method wherein said pharmaceutical formulation is administered daily for at least one month.
[0274] Embodiment III-58. The method of any one of embodiments III-55 to III-57, wherein the pharmaceutical formulation is administered once daily.
[0275] Embodiment III-59. The method of any one of embodiments III-55 to III-57, wherein the pharmaceutical formulation is administered twice daily.
[0276] Embodiment III-60. The method of any one of Embodiments III-55 to III-59, wherein the concentration of azelaic acid is about 1% to about 20%.
[0277] Embodiment III-61. The method of any one of Embodiments III-55 to III-60, wherein the concentration of azelaic acid is about 10% to about 15%.
[0278] Embodiment III-62. The method of any one of embodiments III-55 to III-61, wherein the pharmaceutical formulation further comprises at least one skin penetration enhancer.
[0279] Embodiment III-63. The method of any one of embodiments III-55 to III-62, wherein the pharmaceutical formulation is administered daily for at least two months.
[0280] Embodiment III-64. The method of any one of embodiments III-55 to III-63, wherein the pharmaceutical formulation is administered daily for at least 6 months.
[0281] Embodiment III-65. The method of any one of embodiments III-55 to III-64, wherein the pharmaceutical formulation is administered daily for at least one year.
[0282] Embodiment III-66. The method of any one of embodiments III-55 to III-65, wherein the pharmaceutical formulation is administered as a cream, gel, suspension, solution, ointment, or spray.
[0283] Embodiment III-67. The method of any one of embodiments III-55 to III-65, wherein the pharmaceutical formulation is administered as drops.
[0284] Embodiment III-68. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antibacterial dose of azithromycin.
[0285] Embodiment III-69. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antiparasitic dose of avermectin.
[0286] Embodiment III-70. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antibacterial dose of azithromycin and a sub-antiparasitic dose of avermectin.
[0287] Embodiment III-71. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antibacterial dose of azithromycin or a sub-antiparasitic dose of avermectin, and further comprising an immunosuppressant.
[0288] Embodiment III-72. A pharmaceutical formulation for treating an ophthalmic condition comprising a sub-antibacterial dose of azithromycin or a sub-antiparasitic dose of avermectin, and further comprising azelaic acid.
[0289] Embodiment III-73. The pharmaceutical formulation of embodiment III-72, comprising about 0.4% to 0.5% azithromycin and about 10% to 15% azelaic acid.
[0290] Embodiment III-74. A pharmaceutical formulation for treating an ophthalmic condition, comprising azelaic acid.
[0291] Embodiment III-75. The pharmaceutical formulation of embodiment III-74, comprising about 10% to 15% azelaic acid.
[0292] Embodiment III-76. A method for treating dry eye disease, treating blepharitis, or increasing meibum secretion in a subject in need thereof, comprising: a) about 5% to about 15% azelaic acid, and b) about 0.4% to about 0.5% azithromycin to the eyelid of the subject,
[0293] The method wherein the pharmaceutical formulation is administered daily for at least one month.
[0294] Embodiment III-77. The method of any one of embodiments III-2, III-5, III-34, III-55, or III-76, wherein the blepharitis is caused by Demodex mites.
[0295] Embodiment III-78. The method of embodiment III-76, wherein the azelaic acid addresses anterior blepharitis and the azithromycin addresses posterior blepharitis.
[0296] Embodiment III-79. The pharmaceutical formulation of embodiment III-74 or III-75, wherein the azelaic acid treats anterior blepharitis.
[0297] Embodiment III-80. A method for treating an ophthalmic condition, comprising: a) Azithromycin at subantibacterial doses; b) subantiparasitic doses of avermectin; c) subantibacterial doses of azithromycin and subantiparasitic doses of avermectin; d) further comprising a sub-antibacterial dose of azithromycin or a sub-antiparasitic dose of avermectin, and an immunosuppressant; e) further comprising a sub-antibacterial dose of azithromycin or a sub-antiparasitic dose of avermectin, and azelaic acid; or f) azelaic acid; administering to a subject a pharmaceutical formulation comprising The method wherein the pharmaceutical formulation is administered to the eyelid daily for at least one month.
[0298] Embodiment III-81. The method of embodiment III-80, wherein the ophthalmic condition is one or more of dry eye disease, blepharitis, and meibomian gland dysfunction.
[0299] Embodiment III-82. The pharmaceutical formulation of any one of embodiments III-68 to III-75, wherein the ophthalmic condition is one or more of dry eye disease, blepharitis, and meibomian gland dysfunction.
[0300] Embodiment III-83. A method of treating dry eye disease, comprising administering to an outer surface of a subject's eyelid a pharmaceutical formulation comprising azelaic acid, wherein administration of the pharmaceutical formulation alleviates a symptom of dry eye disease.
[0301] Embodiment III-84. The method of embodiment III-83, wherein the dry eye disease is aqueous-deficient dry eye.
[0302] Embodiment III-85. The method of embodiment III-83, wherein the dry eye disease is evaporative dry eye.
[0303] Embodiment III-86. The method of embodiment III-83, wherein said symptom of dry eye disease is meibomian gland dysfunction, redness, stinging, burning, itching, light sensitivity, watery eyes, blurred vision, ocular surface irregularities, or damage to the epithelium and tissue of the cornea or conjunctiva.
[0304] Embodiment III-87. The method of embodiment III-83, wherein said administering said pharmaceutical formulation further improves the quantity or quality of meibum produced.
[0305] Embodiment III-88 The method of embodiment III-83, wherein the dry eye disease does not result from tissue infection or inflammation.
[0306] Embodiment III-89. The method of embodiment III-83, wherein the pharmaceutical formulation is administered daily.
[0307] Embodiment III-90 The method of embodiment III-83, wherein the pharmaceutical formulation is administered twice daily.
[0308] Embodiment III-91 The method of embodiment III-83, wherein the pharmaceutical formulation is administered daily for at least 6 months.
[0309] Embodiment III-92 The method of embodiment III-83, wherein the pharmaceutical formulation is administered daily for at least one year.
[0310] Embodiment III-93 The method of embodiment III-83, wherein the pharmaceutical formulation is administered as a cream, gel, suspension, solution, ointment, or spray.
[0311] Embodiment III-94. The method of embodiment III-93, wherein the pharmaceutical formulation is administered as a cream.
[0312] Embodiment III-95. The method of embodiment III-93, wherein the pharmaceutical formulation is administered as a gel.
[0313] Embodiment III-96. The method of embodiment III-83, wherein the concentration of azelaic acid in the pharmaceutical formulation is about 1% to about 20%.
[0314] Embodiment III-97. The method of embodiment III-96, wherein the concentration of azelaic acid in the pharmaceutical formulation is about 10% to about 15%.
[0315] Embodiment III-98 The method of embodiment III-83, wherein the pharmaceutical formulation further comprises azithromycin.
[0316] Embodiment III-99. The method of embodiment III-98, wherein the concentration of azithromycin in the pharmaceutical formulation is about 0.1% to 0.5%.
[0317] Embodiment III-100 The method of embodiment III-83, wherein the pharmaceutical formulation further comprises an avermectin.
[0318] Embodiment III-101. The method of embodiment III-98, wherein the concentration of the avermectin in the pharmaceutical formulation is about 0.1% to 0.5%.
[0319] Embodiment III-102. The method of embodiment III-100, wherein the avermectin is ivermectin.
[0320] Embodiment III-103 The method of embodiment III-83, wherein the pharmaceutical formulation further comprises at least one skin penetration enhancer.
[0321] Embodiment III-104. A method of treating blepharitis, comprising administering to the outer surface of the eyelid of a subject a pharmaceutical formulation comprising azelaic acid, wherein administration of the pharmaceutical formulation alleviates symptoms of blepharitis.
[0322] Embodiment III-105. The method of embodiment III-104, wherein the blepharitis is anterior blepharitis.
[0323] Embodiment III-106. The method of embodiment III-104, wherein the blepharitis is posterior blepharitis.
[0324] Embodiment III-107. The method of embodiment III-104, wherein the symptom of blepharitis is irritation, redness, itching, burning, swelling, or crusting.
[0325] Embodiment III-108. The method of embodiment III-104, wherein said administering said pharmaceutical formulation further improves the quantity or quality of meibum produced.
[0326] Embodiment III-109. The method of embodiment III-104, wherein the blepharitis does not result from a bacterial or parasitic infection.
[0327] Embodiment III-110 The method of embodiment III-104, wherein the pharmaceutical formulation is administered daily.
[0328] Embodiment III-111 The method of embodiment III-104, wherein the pharmaceutical formulation is administered twice daily.
[0329] Embodiment III-112 The method of embodiment III-110, wherein the pharmaceutical formulation is administered daily for at least 6 months.
[0330] Embodiment III-113 The method of embodiment III-110, wherein the pharmaceutical formulation is administered daily for at least one year.
[0331] Embodiment III-114 The method of embodiment III-104, wherein the pharmaceutical formulation is administered as a cream, gel, suspension, solution, ointment, or spray.
[0332] Embodiment III-115. The method of embodiment III-114, wherein the pharmaceutical formulation is administered as a cream.
[0333] Embodiment III-116 The method of embodiment III-114, wherein the pharmaceutical formulation is administered as a gel.
[0334] Embodiment III-117. The method of embodiment III-104, wherein the concentration of azelaic acid in the pharmaceutical formulation is about 1% to about 20%.
[0335] Embodiment III-118. The method of embodiment III-117, wherein the concentration of azelaic acid in the pharmaceutical formulation is about 10% to about 15%.
[0336] Embodiment III-119 The method of embodiment III-104, wherein the pharmaceutical formulation further comprises azithromycin.
[0337] Embodiment III-120. The method of embodiment III-119, wherein the concentration of azithromycin in the pharmaceutical formulation is about 0.1% to 0.5%.
[0338] Embodiment III-121 The method of embodiment III-104, wherein the pharmaceutical formulation further comprises an avermectin.
[0339] Embodiment III-122. The method of embodiment III-121, wherein the concentration of the avermectin in the pharmaceutical formulation is about 0.1% to 0.5%.
[0340] Embodiment III-123 The method of embodiment III-104, wherein the pharmaceutical formulation further comprises at least one skin penetration enhancer.
[0341] Embodiment III-124. A method for increasing meibum secretion, comprising administering to the outer surface of the eyelid of a subject a pharmaceutical formulation comprising azelaic acid, wherein said administration of said pharmaceutical formulation alleviates symptoms of insufficient tear production or poor tear quality.
[0342] Embodiment III-125. The method of embodiment III-124, wherein the fluidity of meibum is increased.
[0343] Embodiment III-126. The method of embodiment III-124, wherein the melting temperature of the meibum is reduced.
[0344] Embodiment III-126B. The method of embodiment III-124, wherein the symptom of insufficient tear production or poor tear quality is excessive evaporation of water from the ocular surface.
[0345] Embodiment III-127. The method of embodiment III-124, wherein the symptoms of insufficient tear production or poor tear quality are redness, stinging, burning, itching, light sensitivity, watery eyes, blurred vision, ocular surface irregularities, or damage to the corneal or conjunctival epithelium and tissue.
[0346] Embodiment III-128 The method of embodiment III-124, wherein the pharmaceutical formulation is administered daily.
[0347] Embodiment III-129 The method of embodiment III-124, wherein the pharmaceutical formulation is administered twice daily.
[0348] Embodiment III-130 The method of embodiment III-128, wherein the pharmaceutical formulation is administered daily for at least 6 months.
[0349] Embodiment III-131 The method of embodiment III-128, wherein the pharmaceutical formulation is administered daily for at least one year.
[0350] Embodiment III-132 The method of embodiment III-124, wherein the pharmaceutical formulation is administered as a cream, gel, suspension, solution, ointment, or spray.
[0351] Embodiment III-133. The method of embodiment III-132, wherein the pharmaceutical formulation is administered as a cream.
[0352] Embodiment III-134. The method of embodiment III-132, wherein the pharmaceutical formulation is administered as a gel.
[0353] Embodiment III-135. The method of embodiment III-124, wherein the concentration of azelaic acid in the pharmaceutical formulation is about 1% to about 20%.
[0354] Embodiment III-136. The method of embodiment III-135, wherein the concentration of azelaic acid in the pharmaceutical formulation is about 10% to about 15%.
[0355] Embodiment III-137 The method of embodiment III-124, wherein the pharmaceutical formulation further comprises azithromycin.
[0356] Embodiment III-138 The method of embodiment III-137, wherein the concentration of azithromycin in the pharmaceutical formulation is about 0.1% to 0.5%.
[0357] Embodiment III-139 The method of embodiment III-124, wherein the pharmaceutical formulation further comprises an avermectin.
[0358] Embodiment III-140. A method for treating dry eye disease, comprising: a) about 1% to about 20% azelaic acid, and b) about 0.1% to about 0.5% azithromycin; to the outer surface of the eyelid of a subject, The pharmaceutical formulation is administered to the outer surface of the eyelid daily for at least one month, and administering the pharmaceutical formulation reduces symptoms of dry eye disease.
[0359] Embodiment III-141. The method of embodiment III-140, wherein said symptom of dry eye disease is meibomian gland dysfunction, redness, stinging, burning, itching, light sensitivity, watery eyes, blurred vision, ocular surface irregularities, or damage to the corneal or conjunctival epithelium and tissue.
[0360] Embodiment III-142. The method of embodiment III-140, wherein the dry eye disease is aqueous tear-deficient dry eye (ADDE).
[0361] Embodiment III-143 The method of embodiment III-140, wherein the dry eye disease is evaporative dry eye (EDE).
[0362] Embodiment III-144. The method of embodiment III-140, wherein ADDE and EDE are treated simultaneously.
[0363] Embodiment III-145. The method of embodiment III-140, wherein said administering said pharmaceutical formulation further reduces symptoms of blepharitis.
[0364] Embodiment III-146. The method of embodiment III-145, wherein the blepharitis is anterior blepharitis.
[0365] Embodiment III-147. The method of embodiment III-145, wherein the blepharitis is posterior blepharitis.
[0366] Embodiment III-148. The method of embodiment III-145, wherein the blepharitis is both anterior and posterior blepharitis.
[0367] Embodiment III-149. The method of embodiment III-140, wherein said administering said pharmaceutical formulation further improves the quantity or quality of meibum produced.
[0368] Embodiment III-150 The method of embodiment III-140, wherein the dry eye disease is not due to a bacterial infection, a parasitic infection, or tissue inflammation.
[0369] Embodiment III-151. The method of embodiment III-140, wherein the concentration of azelaic acid is about 5% to 20%.
[0370] Embodiment III-152. The method of embodiment III-140, wherein the concentration of azelaic acid is about 5% to 15%.
[0371] Embodiment III-153. The method of embodiment III-140, wherein the concentration of azelaic acid is about 5% to 15% and the concentration of azithromycin is about 0.4% to about 0.5%.
[0372] Embodiment III-154 The method of embodiment III-140, wherein the concentration of azelaic acid is about 10% and the concentration of azithromycin is about 0.4%.
[0373] Embodiment III-155 The method of embodiment III-140, wherein the pharmaceutical formulation is administered twice daily.
[0374] Embodiment III-156 The method of embodiment III-140, wherein the pharmaceutical formulation is administered daily for at least 6 months.
[0375] Embodiment III-157 The method of embodiment III-140, wherein the pharmaceutical formulation is administered daily for at least one year.
[0376] Embodiment III-158 The method of embodiment III-140, wherein the pharmaceutical formulation is administered as a cream, gel, suspension, solution, ointment, or spray.
[0377] Embodiment III-159. The method of embodiment III-158, wherein the pharmaceutical formulation is administered as a cream.
[0378] Embodiment III-160 The method of embodiment III-158, wherein the pharmaceutical formulation is administered as a gel.
[0379] Embodiment III-161. The method of embodiment III-140, wherein the pharmaceutical formulation further comprises at least one skin penetration enhancer.
[0380] Embodiment III-162. The method of any one of embodiments III-1 to III-32, III-55 to III-67, and III-76 to III-161, wherein the pharmaceutical formulation further comprises at least one polyol.
[0381] Embodiment III-163. The method of any one of Embodiments III-33 to III-54, wherein the first pharmaceutical formulation and the second pharmaceutical formulation each independently comprise at least one polyol.
[0382] Embodiment III-164. The pharmaceutical formulation of any one of embodiments III-68 to III-75, wherein the pharmaceutical formulation further comprises at least one polyol.
[0383] Embodiment III-165. The method of embodiment III-162 or III-163, wherein the at least one polyol is selected from propylene glycol, polyethylene glycol, glycerol, erythritol, mannitol, or sorbitol.
[0384] Embodiment III-166 The method of embodiment III-165, wherein the at least one polyol is propylene glycol.
[0385] Embodiment III-167. A pharmaceutical formulation comprising about 1% to about 20% azelaic acid and about 0.1% to about 0.5% azithromycin.
[0386] Embodiment III-168. Use of a pharmaceutical formulation according to any one of embodiments III-68 to III-75 or III-167 in the manufacture of a medicament for treating an ocular condition or for increasing meibum secretion.
[0387] Embodiment III-169. Use of the pharmaceutical formulation of any one of embodiments III-68 to III-75 or III-167 as a medicament for treating the ocular condition or for increasing meibum secretion.
[0388] Embodiment III-170. Use of the pharmaceutical formulation of any one of embodiments III-68 to III-75 or III-167 for treating the ocular condition or increasing meibum secretion.
[0389] Embodiment III-171. The use of any one of embodiments III-168 to III-170, wherein the condition of the eye is dry eye disease or blepharitis. [Example]
[0390] Example Example 1: Human clinical trials for pharmaceutical formulations Human subjects diagnosed with dry eye disease are assigned to treatment with one of four formulations: (1) azithromycin, (2) azelaic acid, (3) azithromycin and azelaic acid, or (4) vehicle only. Each patient undergoes baseline examinations of visual acuity, intraocular pressure, slit-lamp examination, conjunctival and corneal staining, meibomian gland scoring, tear film breakup time, SPEED questionnaire, and Subjective Dry Eye Questionnaire (SANDE).
[0391] Subjects will be treated with each formulation at night or twice daily for at least one month. Subjects will be examined at weeks 1, 2, and 4. Study endpoints will be based on tear breakup time, meibomian gland score, corneal and conjunctival staining (a decrease is preferable; an increase may indicate toxicity), and questionnaires. Toxicity will be detected by increased corneal or conjunctival staining. Patients may be evaluated by one or more of matrix metalloproteinase activity, meibomian gland secretion scoring, lipid layer interferometry, tear breakup time, subjective questionnaires (SPEED, OSDI, SANDE), corneal and conjunctival staining, meibomian gland obstruction, or tear osmolality.
Claims
1. An ophthalmic insert comprising azithromycin for use in a method for treating dry eye disease (DED), the method comprising inserting the ophthalmic insert into an eye of a subject, wherein the ophthalmic insert releases azithromycin to the eye at less than an antibacterial dose to alleviate symptoms of the DED.
2. An ophthalmic insert as described in claim 1, characterized in that the ophthalmic insert is inserted into the fornix of the eye.
3. An ophthalmic insert as described in claim 1, characterized in that the ophthalmic insert is inserted into the cul-de-sac of the eye.
4. The ophthalmic insert of claim 1, wherein the ophthalmic insert comprises a formulation comprising azithromycin and a pharma- ceutically acceptable carrier.
5. The ophthalmic insert of claim 4, wherein the carrier comprises a solid filler.
6. The ophthalmic insert of claim 4, wherein the carrier comprises a disintegrant.
7. An ophthalmic insert as described in claim 4, wherein the carrier is selected to obtain a release profile of azithromycin less than the antibacterial dose over a period of at least six months.
8. The ophthalmic insert of claim 4, wherein the formulation comprises a high molecular weight, anionic mucosomimetic polymer, a gelling polysaccharide, a finely divided drug carrier substrate, or a combination thereof.
9. The ophthalmic insert of claim 1, wherein the DED is aqueous deficient dry eye (ADDE) or evaporative dry eye (EDE).
10. The ophthalmic insert of claim 1, wherein the dry eye disease is ADDE and EDE, and the ADDE and EDE are treated simultaneously.
11. The ophthalmic insert of claim 1, wherein the symptoms of dry eye disease are meibomian gland dysfunction, redness, stinging, burning, itching, light sensitivity, watery eyes, blurred vision, ocular surface irregularities, damage to the corneal or conjunctival epithelium and tissue, or a combination thereof.
12. The ophthalmic insert of claim 1, wherein the sub-antibacterial dose of azithromycin from the ophthalmic insert increases tear film breakup time, increases meibomian gland secretion score, reduces corneal staining, reduces conjunctival staining, or a combination thereof.
13. The ophthalmic insert of claim 1, wherein the less than antibacterial dose of azithromycin from the ophthalmic insert reduces symptoms of blepharitis.
14. The ophthalmic insert of claim 1, wherein the sub-antibacterial dose of azithromycin from the ophthalmic insert improves the quantity or quality of meibum produced.
15. The ophthalmic insert of claim 1, wherein the DED is not due to bacterial infection, parasitic infection or tissue inflammation.
16. The ophthalmic insert of claim 1, wherein the ophthalmic insert maintains the release of azithromycin to the eye at less than the antibacterial dose for a sustained period between at least one month and at least one year.
17. An ophthalmic insert comprising a formulation comprising azithromycin and a pharma- ceutically acceptable carrier, the ophthalmic insert being configured to provide a sustained release of azithromycin to the eye at less than an antibacterial dose to relieve symptoms of dry eye disease (DED).
18. The ophthalmic insert of claim 17, wherein the carrier comprises a solid filler or a disintegrant.
19. The ophthalmic insert of claim 17, wherein the ophthalmic insert is configured to be inserted into the cul-de-sac of the eye.
20. The ophthalmic insert of claim 17, wherein the formulation comprises a high molecular weight, anionic mucosomimetic polymer, a gelling polysaccharide, a finely divided drug carrier substrate, or a combination thereof.
